# EDGAR Filing Document

**Accession Number:** 0000200406
**File Stem:** 0000200406-25-000209
**Filing Date:** 2025-10
**Character Count:** 248984
**Document Hash:** 869927e5d23b77b02f212af2a68ec726
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000200406-25-000209.hdr.sgml**: 20251022

**ACCESSION NUMBER**: 0000200406-25-000209

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 95

**CONFORMED PERIOD OF REPORT**: 20250928

**FILED AS OF DATE**: 20251022

**DATE AS OF CHANGE**: 20251022

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** JOHNSON & JOHNSON
- **CENTRAL INDEX KEY:** 0000200406
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 221024240
- **STATE OF INCORPORATION:** NJ
- **FISCAL YEAR END:** 1228

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-03215
- **FILM NUMBER:** 251410136

**BUSINESS ADDRESS:**
- **STREET 1:** ONE JOHNSON & JOHNSON PLZ
- **CITY:** NEW BRUNSWICK
- **STATE:** NJ
- **ZIP:** 08933
- **BUSINESS PHONE:** 732-524-2455

**MAIL ADDRESS:**
- **STREET 1:** ONE JOHNSON & JOHNSON PLZ
- **CITY:** NEW BRUNSWICK
- **STATE:** NJ
- **ZIP:** 08933

?xml version='1.0' encoding='ASCII'? jnj-20250928

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q** 

---

| | |
|:---|:---|
| ☑ | **Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934** |

---

**for the quarterly period ended September 28, 2025** 

**or**

☐ **Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934** **for the transition period from&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to**

**Commission file number 1-3215** 

Johnson & Johnson

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **New Jersey** | **22-1024240** |
| (State or other jurisdiction of<br>incorporation or organization) | (I.R.S. Employer<br>Identification No.) |

---

**One Johnson & Johnson Plaza** 

**New Brunswick, New Jersey 08933** 

**(Address of principal executive offices)**

**Registrant's telephone number, including area code (732) 524-0400** 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;for the past 90 days. ☑ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☑ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☑ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
| Emerging growth company | ☐ | | |

---

If an emerging growth company, indicated by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☑ No

**SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol** | **Name of each exchange on which registered** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common Stock, Par Value $1.00 | JNJ | New York Stock Exchange |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.150% Notes Due November 2028 | JNJ28 | New York Stock Exchange |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.700% Notes Due February 2029 | JNJ29B | New York Stock Exchange |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.200% Notes Due June 2032 | JNJ32 | New York Stock Exchange |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.050% Notes Due February 2033 | JNJ33B | New York Stock Exchange |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.650% Notes Due May 2035 | JNJ35 | New York Stock Exchange |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.350% Notes Due June 2036 | JNJ36A | New York Stock Exchange |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.350% Notes Due February 2037 | JNJ37B | New York Stock Exchange |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.550% Notes Due June 2044 | JNJ44 | New York Stock Exchange |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.600% Notes Due February 2045 | JNJ45 | New York Stock Exchange |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.700% Notes Due February 2055 | JNJ55 | New York Stock Exchange |

---

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

On October 17, 2025, 2,409,295,102 shares of Common Stock, $1.00 par value, were outstanding.

------

JOHNSON & JOHNSON AND SUBSIDIARIES

**Table of contents**

---

| | | |
|:---|:---|:---|
| **Item** | **Item** | Page |
| **Part I** | **Part I** | **Part I** |
| | [Financial information](#i056ba067237e4aedb74b3ac320710725_13) | [1](#i056ba067237e4aedb74b3ac320710725_13) |
| **[Item 1](#i056ba067237e4aedb74b3ac320710725_16)** | **[Financial statements (unaudited)](#i056ba067237e4aedb74b3ac320710725_16)** | **[1](#i056ba067237e4aedb74b3ac320710725_16)** |
| | [Consolidated balance sheets —](#i056ba067237e4aedb74b3ac320710725_19)[September](#i056ba067237e4aedb74b3ac320710725_19)[2](#i056ba067237e4aedb74b3ac320710725_19)[8](#i056ba067237e4aedb74b3ac320710725_19)[, 2025 and December 29, 2024](#i056ba067237e4aedb74b3ac320710725_19) | [1](#i056ba067237e4aedb74b3ac320710725_19) |
| | [Consolidated statements of earnings for the fiscal](#i056ba067237e4aedb74b3ac320710725_25)[third](#i056ba067237e4aedb74b3ac320710725_25)[quarters ended](#i056ba067237e4aedb74b3ac320710725_25)[September](#i056ba067237e4aedb74b3ac320710725_25)[2](#i056ba067237e4aedb74b3ac320710725_25)[8](#i056ba067237e4aedb74b3ac320710725_25)[, 2025](#i056ba067237e4aedb74b3ac320710725_25)[and](#i056ba067237e4aedb74b3ac320710725_25)[September](#i056ba067237e4aedb74b3ac320710725_25)[29](#i056ba067237e4aedb74b3ac320710725_25)[, 2024](#i056ba067237e4aedb74b3ac320710725_25) | [2](#i056ba067237e4aedb74b3ac320710725_25) |
| | [Consolidated statements of earnings for the fiscal](#i056ba067237e4aedb74b3ac320710725_28)[nine](#i056ba067237e4aedb74b3ac320710725_28)[months ended](#i056ba067237e4aedb74b3ac320710725_28)[Sept](#i056ba067237e4aedb74b3ac320710725_28)[ember](#i056ba067237e4aedb74b3ac320710725_28)[2](#i056ba067237e4aedb74b3ac320710725_28)[8](#i056ba067237e4aedb74b3ac320710725_28)[, 2025](#i056ba067237e4aedb74b3ac320710725_28)[and](#i056ba067237e4aedb74b3ac320710725_28)[September](#i056ba067237e4aedb74b3ac320710725_28)[29](#i056ba067237e4aedb74b3ac320710725_28)[, 2024](#i056ba067237e4aedb74b3ac320710725_28) | [3](#i056ba067237e4aedb74b3ac320710725_28) |
| | [Consolidated statements of comprehensive income for the fiscal](#i056ba067237e4aedb74b3ac320710725_31)[third](#i056ba067237e4aedb74b3ac320710725_31)[quarters and fiscal](#i056ba067237e4aedb74b3ac320710725_31)[nine](#i056ba067237e4aedb74b3ac320710725_31)[months ended](#i056ba067237e4aedb74b3ac320710725_31)[Sept](#i056ba067237e4aedb74b3ac320710725_31)[e](#i056ba067237e4aedb74b3ac320710725_31)[m](#i056ba067237e4aedb74b3ac320710725_31)[ber](#i056ba067237e4aedb74b3ac320710725_31)[2](#i056ba067237e4aedb74b3ac320710725_31)[8](#i056ba067237e4aedb74b3ac320710725_31)[, 2025 and](#i056ba067237e4aedb74b3ac320710725_31)[September](#i056ba067237e4aedb74b3ac320710725_31)[29](#i056ba067237e4aedb74b3ac320710725_31)[, 2024](#i056ba067237e4aedb74b3ac320710725_31) | [4](#i056ba067237e4aedb74b3ac320710725_31) |
| | [Consolidated statements of equity for the fiscal](#i056ba067237e4aedb74b3ac320710725_37)[th](#i056ba067237e4aedb74b3ac320710725_37)[ird](#i056ba067237e4aedb74b3ac320710725_37)[quarters and fiscal](#i056ba067237e4aedb74b3ac320710725_37)[nine](#i056ba067237e4aedb74b3ac320710725_37)[months ended](#i056ba067237e4aedb74b3ac320710725_37)[September](#i056ba067237e4aedb74b3ac320710725_37)[2](#i056ba067237e4aedb74b3ac320710725_37)[8](#i056ba067237e4aedb74b3ac320710725_37)[, 2025 and](#i056ba067237e4aedb74b3ac320710725_37)[September](#i056ba067237e4aedb74b3ac320710725_37)[29](#i056ba067237e4aedb74b3ac320710725_37)[, 2024](#i056ba067237e4aedb74b3ac320710725_37) | [5](#i056ba067237e4aedb74b3ac320710725_37) |
| | [Consolidated statements of cash flows for the fiscal](#i056ba067237e4aedb74b3ac320710725_43)[nine](#i056ba067237e4aedb74b3ac320710725_43)[months ended](#i056ba067237e4aedb74b3ac320710725_43)[September](#i056ba067237e4aedb74b3ac320710725_43)[2](#i056ba067237e4aedb74b3ac320710725_43)[8](#i056ba067237e4aedb74b3ac320710725_43)[, 2025](#i056ba067237e4aedb74b3ac320710725_43)[and](#i056ba067237e4aedb74b3ac320710725_43)[September](#i056ba067237e4aedb74b3ac320710725_43)[29](#i056ba067237e4aedb74b3ac320710725_43)[, 2024](#i056ba067237e4aedb74b3ac320710725_43) | [7](#i056ba067237e4aedb74b3ac320710725_43) |
| | [Notes to consolidated financial statements](#i056ba067237e4aedb74b3ac320710725_46) | [8](#i056ba067237e4aedb74b3ac320710725_46) |
| **[Item 2](#i056ba067237e4aedb74b3ac320710725_112)** | **[Management's discussion and analysis of financial condition and results of operations](#i056ba067237e4aedb74b3ac320710725_112)** | **[41](#i056ba067237e4aedb74b3ac320710725_112)** |
| **[Item 3](#i056ba067237e4aedb74b3ac320710725_115)** | **[Quantitative and qualitative disclosures about market risk](#i056ba067237e4aedb74b3ac320710725_115)** | **[57](#i056ba067237e4aedb74b3ac320710725_115)** |
| **[Item 4](#i056ba067237e4aedb74b3ac320710725_118)** | **[Controls and procedures](#i056ba067237e4aedb74b3ac320710725_118)** | **[57](#i056ba067237e4aedb74b3ac320710725_118)** |
| **[Part II](#i056ba067237e4aedb74b3ac320710725_121)** | **[Part II](#i056ba067237e4aedb74b3ac320710725_121)** | **[Part II](#i056ba067237e4aedb74b3ac320710725_121)** |
| | [Other information](#i056ba067237e4aedb74b3ac320710725_121) | [58](#i056ba067237e4aedb74b3ac320710725_121) |
| **[Item 1](#i056ba067237e4aedb74b3ac320710725_124)** | **[Legal proceedings](#i056ba067237e4aedb74b3ac320710725_124)** | **[58](#i056ba067237e4aedb74b3ac320710725_124)** |
| **[Item 2](#i056ba067237e4aedb74b3ac320710725_127)** | **[Unregistered sales of equity securities and use of proceeds](#i056ba067237e4aedb74b3ac320710725_127)** | **[58](#i056ba067237e4aedb74b3ac320710725_127)** |
| **[Item 5](#i056ba067237e4aedb74b3ac320710725_130)** | **[Other information](#i056ba067237e4aedb74b3ac320710725_130)** | **[59](#i056ba067237e4aedb74b3ac320710725_130)** |
| **[Item 6](#i056ba067237e4aedb74b3ac320710725_136)** | **[Exhibits](#i056ba067237e4aedb74b3ac320710725_136)** | **[59](#i056ba067237e4aedb74b3ac320710725_136)** |
| | [Signatures](#i056ba067237e4aedb74b3ac320710725_139) | [60](#i056ba067237e4aedb74b3ac320710725_139) |

---

------

**Cautionary note regarding forward-looking statements**

This Quarterly Report on Form 10-Q and Johnson & Johnson's other publicly available documents contain "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Management and representatives of Johnson & Johnson and its subsidiaries (the Company) also may from time to time make forward-looking statements. Forward-looking statements do not relate strictly to historical or current facts and reflect management's assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as "plans," "expects," "will," "anticipates," "estimates," and other words of similar meaning in conjunction with, among other things: discussions of future operations, expected operating results, financial performance; impact of planned acquisitions and dispositions; impact and timing of restructuring initiatives including associated cost savings and other benefits; the Company's strategy for growth; product development activities; regulatory approvals; market position and expenditures.

Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they are subject to uncertainties, risks and changes that are difficult to predict and many of which are outside of the Company's control. Investors should realize that if underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, the Company's actual results and financial condition could vary materially from expectations and projections expressed or implied in its forward-looking statements. Investors are therefore cautioned not to rely on these forward-looking statements. Risks and uncertainties include, but are not limited to:

***Risks related to product development, market success and competition***

**•** Challenges and uncertainties inherent in innovation and development of new and improved products and technologies on which the Company's continued growth and success depend, including uncertainty of clinical outcomes, additional analysis of existing clinical data, obtaining regulatory approvals, health plan coverage and customer access, and initial and continued commercial success;

**•** Challenges to the Company's ability to secure and maintain adequate patent and other intellectual property rights for new and existing products and technologies in the United States and other important markets;

**•** The impact of patent expirations, typically followed by the introduction of competing generic, biosimilar or other products and resulting revenue and market share losses;

**•** Increasingly aggressive and frequent challenges to the Company's patents by competitors and others seeking to launch competing generic, biosimilar or other products and increased receptivity of courts, the United States Patent and Trademark Office and other decision makers to such challenges, potentially resulting in loss of market exclusivity and rapid decline in sales for the relevant product sooner than expected;

**•** Competition in research and development of new and improved products, processes and technologies, which can result in product and process obsolescence;

**•** Competition to reach agreement with third parties for collaboration, licensing, development and marketing agreements for products and technologies;

**•** Competition based on cost-effectiveness, product performance, technological advances and patents attained by competitors; and

**•** Allegations that the Company's products infringe the patents and other intellectual property rights of third parties, which could adversely affect the Company's ability to sell the products in question and require the payment of money damages and future royalties.

***Risks related to product liability, litigation and regulatory activity***

**•** Product efficacy or safety concerns, whether or not based on scientific evidence, potentially resulting in product withdrawals, recalls, regulatory action on the part of the United States Food and Drug Administration (U.S. FDA) (or international counterparts), declining sales, reputational damage, increased litigation expense and share price impact;

**•** The impact, including declining sales and reputational damage, of significant litigation or government action adverse to the Company, including product liability claims and allegations related to pharmaceutical marketing practices and contracting strategies;

**•** The impact of an adverse judgment or settlement and the adequacy of reserves related to legal proceedings, including patent litigation, product liability, personal injury claims, securities class actions, government investigations, employment and other legal proceedings;

------

**•** Increased scrutiny of the healthcare industry by government agencies and state attorneys general resulting in investigations and prosecutions, which carry the risk of significant civil and criminal penalties, including, but not limited to, debarment from government business;

**•** Failure to meet compliance obligations in compliance agreements with governments or government agencies, which could result in significant sanctions;

**•** Potential changes to applicable laws and regulations affecting United States and international operations, including relating to: approval of new products; licensing and patent rights; sales and promotion of healthcare products; access to, and reimbursement and pricing for, healthcare products and services; environmental protection; and sourcing of raw materials;

**•** Compliance with local regulations and laws that may restrict the Company's ability to manufacture or sell its products in relevant markets, including requirements to comply with medical device reporting regulations and other requirements such as the European Union's Medical Devices Regulation;

**•** Changes in domestic and international tax laws and regulations, increasing audit scrutiny by tax authorities around the world may cause exposures to additional tax liabilities potentially in excess of existing reserves; and

**•** The issuance of new or revised accounting standards by the Financial Accounting Standards Board and regulations by the Securities and Exchange Commission.

***Risks related to the Company's strategic initiatives, healthcare market trends and the planned separation of the Company's Orthopaedics Business***

**•** Pricing pressures resulting from trends toward healthcare cost containment, including the continued consolidation among healthcare providers and other market participants, trends toward managed care, the shift toward governments increasingly becoming the primary payors of healthcare expenses, significant new entrants to the healthcare markets seeking to reduce costs and government pressure on companies to voluntarily reduce costs and price increases;

**•** Restricted spending patterns of individual, institutional and governmental purchasers of healthcare products and services due to economic hardship and budgetary constraints;

**•** Challenges to the Company's ability to realize its strategy for growth including through externally sourced innovations, such as development collaborations, strategic acquisitions, licensing and marketing agreements, and the potential heightened costs of any such external arrangements due to competitive pressures;

**•** The potential that the expected strategic benefits and opportunities from any planned or completed acquisition or divestiture by the Company may not be realized or may take longer to realize than expected;

**•** The potential that the expected benefits and opportunities related to past and ongoing restructuring actions may not be realized or may take longer to realize than expected.

• The Company's ability to satisfy the necessary conditions to consummate the planned separation of the Company's Orthopaedics business on a timely basis or at all;

**•** The Company's ability to successfully separate the Company's Orthopaedics business and realize the anticipated benefits from the planned separation; and

**•** The structure of the separation transaction and the future operating and financial performance, market position and business strategy for each company.

***Risks related to economic conditions, financial markets and operating internationally***

**•** The risks associated with global operations on the Company and its customers and suppliers, including foreign governments in countries in which the Company operates;

**•** The impact of inflation and fluctuations in interest rates and currency exchange rates and the potential effect of such fluctuations on revenues, expenses and resulting margins;

**•** Potential changes in export/import and trade laws, regulations and policies of the United States and other countries, including any increased trade restrictions or tariffs and potential drug reimportation legislation, and the impact of such changes on raw material prices, supply chains market volatility and the pace of product development;

**•** The impact on international operations from financial instability in international economies, sovereign risk, possible imposition of governmental controls and restrictive economic policies, and unstable international governments and legal systems;

**•** The impact of global public health crises and pandemics;

**•** Changes to global climate, extreme weather and natural disasters that could affect demand for the Company's products and services, cause disruptions in manufacturing and distribution networks, alter the availability of goods and services within the supply chain, and affect the overall design and integrity of the Company's products and operations;

------

**•** The impact of global or economic changes or events, including global tensions and war; and

**•** The impact of armed conflicts and terrorist attacks in the United States and other parts of the world, including social and economic disruptions and instability of financial and other markets.

***Risks related to supply chain and operations***

**•** Difficulties and delays in manufacturing, internally, through third-party providers or otherwise within the supply chain, that may lead to voluntary or involuntary business interruptions or shutdowns, product shortages, withdrawals or suspensions of products from the market, and potential regulatory action;

**•** Interruptions and breaches of the Company's information technology systems or those of the Company's vendors, which could result in reputational, competitive, operational or other business harm as well as financial costs and regulatory action;

**•** Reliance on global supply chains and production and distribution processes that are complex and subject to increasing regulatory requirements that may adversely affect supply, sourcing and pricing of materials used in the Company's products; and

**•** The potential that the expected benefits and opportunities related to restructuring actions may not be realized or may take longer to realize than expected, including due to any required approvals from applicable regulatory authorities.

Investors also should carefully read the Risk Factors described in Item 1A of the Company's Annual Report on Form 10-K for the fiscal year ended December 29, 2024, for a description of certain risks that could, among other things, cause the Company's actual results to differ materially from those expressed in its forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider the risks described above to be a complete statement of all potential risks and uncertainties. The Company does not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments.

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

Part I — Financial information

**Item 1 — Financial statements**

**Johnson & Johnson and subsidiaries consolidated balance sheets**

**(Unaudited; Dollars in Millions Except Share and Per Share Data)**

---

| | | |
|:---|:---|:---|
| | **September 28, 2025** | **December 29, 2024** |
| **Assets** | **Assets** | **Assets** |
| Current assets: |  |  |
| Cash and cash equivalents (Note 4) | $18231 | 24105 |
| Marketable securities | 331 | 417 |
| Accounts receivable, trade, less allowances $176 (2024, $167) | 17611 | 14842 |
| Inventories (Note 2) | 14146 | 12444 |
| Prepaid expenses and other | 4292 | 4085 |
| **Total current assets** | **54611** | **55893** |
| Property, plant and equipment at cost | 53375 | 48768 |
| Less: accumulated depreciation | (31037) | (28250) |
| Property, plant and equipment, net | 22338 | 20518 |
| Intangible assets, net (Note 3) | 48737 | 37618 |
| Goodwill (Note 3) | 48048 | 44200 |
| Deferred taxes on income (Note 5) | 6666 | 10461 |
| Other assets | 12416 | 11414 |
| **Total assets** | **$192816** | **180104** |
| **Liabilities and shareholders' equity** | **Liabilities and shareholders' equity** | **Liabilities and shareholders' equity** |
| Current liabilities: |  |  |
| Loans and notes payable | $6387 | 5983 |
| Accounts payable | 9625 | 10311 |
| Accrued liabilities | 7601 | 8549 |
| Accrued rebates, returns and promotions | 21356 | 17580 |
| Accrued compensation and employee related obligations | 3972 | 4126 |
| Accrued taxes on income (Note 5) | 1928 | 3772 |
| **Total current liabilities** | **50869** | **50321** |
| Long-term debt (Note 4) | 39408 | 30651 |
| Deferred taxes on income (Note 5) | 5988 | 2448 |
| Employee related obligations (Note 6) | 6930 | 7255 |
| Long-term taxes payable (Note 5) | 418 | 390 |
| Other liabilities | 9926 | 17549 |
| **Total liabilities** | **$113539** | **108614** |
| Commitments and Contingencies (Note 11) |  |  |
| Shareholders' equity: |  |  |
| Common stock — par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) | $3120 | 3120 |
| Accumulated other comprehensive income (loss) (Note 7) | (15237) | (11741) |
| Retained earnings and Additional paid-in capital | 167281 | 155791 |
| Less: common stock held in treasury, at cost (713,648,000 and 712,921,000 shares) | 75887 | 75680 |
| **Total shareholders' equity** | **$79277** | **71490** |
| **Total liabilities and shareholders' equity** | **$192816** | **180104** |

---

*See Notes to Consolidated Financial Statements*

Form 10-Q<sub>1</sub>

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

**Johnson & Johnson and subsidiaries consolidated statements of earnings**

**(Unaudited; Dollars & Shares in Millions Except Per Share Amounts)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Fiscal Third Quarter Ended** | **Fiscal Third Quarter Ended** | **Fiscal Third Quarter Ended** | **Fiscal Third Quarter Ended** |
| | **September 28,<br>2025** | **Percent<br>to Sales** | **September 29,<br>2024** | **Percent<br>to Sales** |
| **Sales to customers (Note 9)** | **$23993** | **100.0%** | **$22471** | **100.0%** |
| Cost of products sold | 7303 | 30.4 | 6963 | 31.0 |
| Gross profit | 16690 | 69.6 | 15508 | 69.0 |
| Selling, marketing and administrative expenses | 5922 | 24.7 | 5478 | 24.3 |
| Research and development expense | 3672 | 15.3 | 4952 | 22.0 |
| Interest income | (227) | (0.9) | (292) | (1.3) |
| Interest expense, net of portion capitalized | 245 | 1.0 | 193 | 0.9 |
| Other (income) expense, net | (478) | (2.0) | 1798 | 8.0 |
| Restructuring (Note 12) | 63 | 0.3 | 41 | 0.2 |
| Earnings before provision for taxes on income | 7493 | 31.2 | 3338 | 14.9 |
| Provision for taxes on income (Note 5) | 2341 | 9.7 | 644 | 2.9 |
| **Net earnings** | **$5152** | **21.5%** | **$2694** | **12.0%** |
| **Net earnings per share (Note 8)** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Basic | $2.14 |  | $1.12 |  |
| &nbsp;&nbsp;&nbsp;Diluted | $2.12 |  | $1.11 |  |
| **Avg. shares outstanding** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;**Basic** | **2408.3** |  | **2407.2** |  |
| &nbsp;&nbsp;&nbsp;**Diluted** | **2428.6** |  | **2427.9** |  |

---

*See Notes to Consolidated Financial Statements*

---

| | |
|:---|:---|
| **2** | ![Jhonson&Jhonson.jpg](jnj-20250928_g1.jpg) |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

**Johnson & Johnson and subsidiaries consolidated statements of earnings**

**(Unaudited; Dollars & Shares in Millions Except Per Share Amounts)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Fiscal Nine Months Ended** | **Fiscal Nine Months Ended** | **Fiscal Nine Months Ended** | **Fiscal Nine Months Ended** |
| | **September 28,<br>2025** | **Percent<br>to Sales** | **September 29,<br>2024** | **Percent<br>to Sales** |
| **Sales to customers (Note 9)** | **$69629** | **100.0%** | **$66301** | **100.0%** |
| Cost of products sold | 22288 | 32.0 | 20343 | 30.7 |
| Gross profit | 47341 | 68.0 | 45958 | 69.3 |
| Selling, marketing and administrative expenses | 16923 | 24.3 | 16416 | 24.8 |
| Research and development expense | 10413 | 15.0 | 11934 | 18.0 |
| In-process research and development impairments |  |  | 194 | 0.3 |
| Interest income | (819) | (1.2) | (1051) | (1.6) |
| Interest expense, net of portion capitalized | 757 | 1.1 | 618 | 0.9 |
| Other (income) expense, net | (7692) | (11.1) | 4855 | 7.3 |
| Restructuring (Note 12) | 144 | 0.2 | 192 | 0.3 |
| Earnings before provision for taxes on income | 27615 | 39.7 | 12800 | 19.3 |
| Provision for taxes on income (Note 5) | 5927 | 8.6 | 2165 | 3.3 |
| **Net earnings** | **$21688** | **31.1%** | **$10635** | **16.0%** |
| **Net earnings per share (Note 8)** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Basic | $9.01 |  | $4.42 |  |
| &nbsp;&nbsp;&nbsp;Diluted | $8.94 |  | $4.38 |  |
| **Avg. shares outstanding** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;**Basic** | **2407.3** |  | **2407.4** |  |
| &nbsp;&nbsp;&nbsp;**Diluted** | **2424.8** |  | **2429.5** |  |

---

*See Notes to Consolidated Financial Statements*

Form 10-Q<sub>3</sub>

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

**Johnson & Johnson and subsidiaries consolidated statements of comprehensive income**

**(Unaudited; Dollars in Millions)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Fiscal Third Quarter Ended** | **Fiscal Third Quarter Ended** | **Fiscal Nine Months Ended** | **Fiscal Nine Months Ended** |
| | **September 28, 2025** | **September 29, 2024** | **September 28, 2025** | **September 29, 2024** |
| Net earnings | $5152 | 2694 | $21688 | 10635 |
| Other comprehensive income (loss), net of tax |  |  |  |  |
| Foreign currency translation | (1292) | (1537) | (5031) | 197 |
| Securities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Unrealized holding gain (loss) arising during period |  | 1 | (1) | 2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net change |  | 1 | (1) | 2 |
| Employee benefit plans: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Prior service cost amortization during period | (35) | (40) | (106) | (90) |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain (loss) amortization during period | 82 | 49 | 238 | 160 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net change | 47 | 9 | 132 | 70 |
| Derivatives & hedges: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Unrealized gain (loss) arising during period | 434 | 405 | 1642 | 313 |
| &nbsp;&nbsp;&nbsp;&nbsp;Reclassifications to earnings | (121) | (147) | (238) | (577) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net change | 313 | 258 | 1404 | (264) |
| Other comprehensive income (loss) | (932) | (1269) | (3496) | 5 |
| **Comprehensive income** | **$4220** | **1425** | **$18192** | **10640** |

---

*See Notes to Consolidated Financial Statements*

---

| |
|:---|
| The tax cost/(benefit) effects in other comprehensive income/(loss) for the fiscal third quarter were as follows for 2025 and 2024, respectively: Foreign Currency Translation: $1.1 billion and $735 million; Employee Benefit Plans: $8 million and $1 million; Derivatives & Hedges: $83 million and $69 million. |
| The tax cost/(benefit) effects in other comprehensive income/(loss) for the fiscal nine months were as follows for 2025 and 2024, respectively: Foreign Currency Translation: $2.3 billion and $51 million; Employee Benefit Plans: $29 million and $(40) million; Derivatives & Hedges: $373 million and $(70) million. |

---

---

| | |
|:---|:---|
| **4** | ![Jhonson&Jhonson.jpg](jnj-20250928_g1.jpg) |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

**Johnson & Johnson and subsidiaries consolidated statements of equity**

**(Unaudited; Dollars in Millions)**

**Fiscal Third Quarter Ended September 28, 2025** 

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Total** | **Retained**<br>**Earnings and Additional Paid-in Capital** | **Accumulated<br>Other<br>Comprehensive<br>Income (AOCI)** | **Common Stock<br>Issued Amount** | **Treasury<br>Stock<br>Amount** |
| **Balance, June 29, 2025** | **$78473** | **165371** | **(14305)** | **3120** | **(75713)** |
| Net earnings | 5152 | 5152 |  |  |  |
| Cash dividends paid ($1.30 per share) | (3132) | (3132) |  |  |  |
| Employee compensation and stock option plans | 1620 | (110) |  |  | 1730 |
| Repurchase of common stock (including excise tax) | (1904) |  |  |  | (1904) |
| Other comprehensive income (loss), net of tax | (932) |  | (932) |  |  |
| **Balance, September 28, 2025** | **$79277** | **167281** | **(15237)** | **3120** | **(75887)** |

---

**Fiscal Nine Months Ended September 28, 2025**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Total** | **Retained**<br>**Earnings and Additional Paid-in Capital** | **Accumulated<br>Other<br>Comprehensive<br>Income (AOCI)** | **Common Stock<br>Issued Amount** | **Treasury<br>Stock<br>Amount** |
| **Balance, December 29, 2024** | **$71490** | **155791** | **(11741)** | **3120** | **(75680)** |
| Net earnings | 21688 | 21688 |  |  |  |
| Cash dividends paid ($3.84 per share) | (9250) | (9250) |  |  |  |
| Employee compensation and stock option plans | 2876 | (948) |  |  | 3824 |
| Repurchase of common stock (including excise tax) | (4031) |  |  |  | (4031) |
| Other comprehensive income (loss), net of tax | (3496) |  | (3496) |  |  |
| **Balance, September 28, 2025** | **$79277** | **167281** | **(15237)** | **3120** | **(75887)** |

---

Form 10-Q<sub>5</sub>

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

**Fiscal Third Quarter Ended September 29, 2024** 

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Total** | **Retained**<br>**Earnings and Additional Paid-in Capital** | **Accumulated<br>Other<br>Comprehensive<br>Income** | **Common Stock<br>Issued Amount** | **Treasury<br>Stock<br>Amount** |
| **Balance, June 30, 2024** | **$71538** | **155360** | **(11253)** | **3120** | **(75689)** |
| Net earnings | 2694 | 2694 |  |  |  |
| Cash dividends paid ($1.24 per share) | (2985) | (2985) |  |  |  |
| Employee compensation and stock option plans | 717 | 110 |  |  | 607 |
| Repurchase of common stock | (539) |  |  |  | (539) |
| Other | 2 |  |  |  | 2 |
| Other comprehensive income (loss), net of tax | (1269) |  | (1269) |  |  |
| **Balance, September 29, 2024** | **$70158** | **155179** | **(12522)** | **3120** | **(75619)** |

---

**Fiscal Nine Months Ended September 29, 2024** 

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Total** | **Retained**<br>**Earnings and Additional Paid-in Capital** | **Accumulated<br>Other<br>Comprehensive<br>Income** | **Common Stock<br>Issued Amount** | **Treasury<br>Stock<br>Amount** |
| **Balance, December 31, 2023** | **$68774** | **153843** | **(12527)** | **3120** | **(75662)** |
| Net earnings | 10635 | 10635 |  |  |  |
| Cash dividends paid ($3.67 per share) | (8839) | (8839) |  |  |  |
| Employee compensation and stock option plans | 1732 | (460) |  |  | 2192 |
| Repurchase of common stock | (2150) |  |  |  | (2150) |
| Other | 1 |  |  |  | 1 |
| Other comprehensive income (loss), net of tax | 5 |  | 5 |  |  |
| **Balance, September 29, 2024** | **$70158** | **155179** | **(12522)** | **3120** | **(75619)** |

---

*See Notes to Consolidated Financial Statements*

---

| | |
|:---|:---|
| **6** | ![Jhonson&Jhonson.jpg](jnj-20250928_g1.jpg) |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

**Johnson & Johnson and subsidiaries consolidated statements of cash flows**

**(Unaudited; Dollars in Millions)**

---

| | | |
|:---|:---|:---|
| | **Fiscal Nine Months Ended** | **Fiscal Nine Months Ended** |
| | **September 28,<br>2025** | **September 29,<br>2024** |
| **Cash flows from operating activities** | | |
| Net earnings | $21688 | 10635 |
| Adjustments to reconcile net earnings to cash flows from operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization of property and intangibles | 5492 | 5443 |
| &nbsp;&nbsp;&nbsp;Stock based compensation | 1045 | 938 |
| &nbsp;&nbsp;&nbsp;Asset write-downs | 123 | 379 |
| &nbsp;&nbsp;&nbsp;Charges for acquired in-process research and development assets | 109 | 1252 |
| &nbsp;&nbsp;&nbsp;Net gain on sale of assets/businesses | (131) | (225) |
| &nbsp;&nbsp;&nbsp;Deferred tax provision | 5215 | (2167) |
| &nbsp;&nbsp;&nbsp;Credit losses and accounts receivable allowances | (6) | (11) |
| Changes in assets and liabilities, net of effects from acquisitions and divestitures: |  |  |
| &nbsp;&nbsp;&nbsp;Increase in accounts receivable | (2172) | (1259) |
| &nbsp;&nbsp;&nbsp;Increase in inventories | (1404) | (1038) |
| &nbsp;&nbsp;&nbsp;Increase in accounts payable and accrued liabilities | 1111 | 2713 |
| &nbsp;&nbsp;&nbsp;(Increase)/Decrease in other current and non-current assets | (7653) | 949 |
| &nbsp;&nbsp;&nbsp;Decrease in other current and non-current liabilities | (6196) | (326) |
| **Net cash flows from operating activities** | **17221** | **17283** |
| **Cash flows from investing activities** |  |  |
| Additions to property, plant and equipment | (2995) | (2812) |
| Proceeds from the disposal of assets/businesses, net (Note 10) | 408 | 623 |
| Acquisitions, net of cash acquired (Note 10) | (14459) | (15145) |
| Acquired in-process research and development assets / related milestones (Note 10) | (385) | (1250) |
| Purchases of investments | (677) | (1464) |
| Sales of investments | 1442 | 2172 |
| Credit support agreements activity, net | (2338) | 699 |
| Other (including capitalized licenses and milestones) | (99) | (102) |
| **Net cash used for investing activities** | **(19103)** | **(17279)** |
| **Cash flows from financing activities** |  |  |
| Dividends to shareholders | (9250) | (8839) |
| Repurchase of common stock | (4029) | (2150) |
| Proceeds from short-term debt, net | 10673 | 11984 |
| Repayment of short-term debt, net | (10524) | (8354) |
| Proceeds from long-term debt, net of issuance costs | 9138 | 6660 |
| Repayment of long-term debt | (1755) | (804) |
| Proceeds from the exercise of stock options/employee withholding tax on stock awards, net | 1831 | 714 |
| Credit support agreements activity, net | (246) | 5 |
| Settlement of convertible debt acquired from Shockwave |  | (970) |
| Other | (8) | (38) |
| **Net cash used for financing activities** | **(4170)** | **(1792)** |
| Effect of exchange rate changes on cash and cash equivalents | 178 | (91) |
| Decrease in cash and cash equivalents | (5874) | (1879) |
| Cash and cash equivalents, beginning of period | 24105 | 21859 |
| Cash and cash equivalents, end of period | 18231 | 19980 |

---

*See Notes to Consolidated Financial Statements*

Form 10-Q<sub>7</sub>

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

**Notes to consolidated financial statements**

**Note 1** — The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson & Johnson and its subsidiaries (the Company) and related notes as contained in the Company's Annual Report on Form 10-K for the fiscal year ended December 29, 2024. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented.

Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.

**New accounting standards**

The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company's Annual Report on Form 10-K for the fiscal year ended December 29, 2024.

**Recently adopted accounting standards**

There were no new material accounting standards adopted in the fiscal nine months of 2025.

**Recently issued accounting standards**

There were no new material accounting standards issued in the fiscal nine months of 2025.

**Supplier finance program obligations**

The Company has agreements for supplier finance programs with third-party financial institutions. These programs provide enrolled suppliers the ability to finance payment obligations from the Company with the third-party financial institutions. The Company is not a party to the arrangements between the suppliers and the third-party financial institutions. The Company's obligations to its suppliers, including amounts due, and scheduled payment dates (which have general payment terms of 90 days), are not affected by a participating supplier's decision to join in the program.

Confirmed obligations under the program as of September 28, 2025, and December 29, 2024, were $0.6 billion and $0.8 billion, respectively. The obligations are presented as Accounts payable on the Consolidated Balance Sheets.

**Note 2 — Inventories**

---

| | | |
|:---|:---|:---|
| **(Dollars in Millions)** | **September 28, 2025** | **December 29, 2024** |
| Raw materials and supplies | $2552 | 2337 |
| Goods in process | 3763 | 2815 |
| Finished goods | 7831 | 7292 |
| Total inventories | $14146 | 12444 |

---

---

| | |
|:---|:---|
| **8** | ![Jhonson&Jhonson.jpg](jnj-20250928_g1.jpg) |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

**Note 3 — Intangible assets and goodwill**

Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2024. Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted.

---

| | | |
|:---|:---|:---|
| **(Dollars in Millions)** | **September 28, 2025** | **December 29, 2024** |
| Intangible assets with definite lives: |  |  |
| Patents and trademarks — gross | $54026 | 44695 |
| Less accumulated amortization | (31339) | (26124) |
| Patents and trademarks — net | **$22687** | **18571** |
| Customer relationships and other intangibles — gross | 21179 | 20310 |
| Less accumulated amortization | (14710) | (13544) |
| Customer relationships and other intangibles — net<sup>(1)</sup> | **$6469** | **6766** |
| Intangible assets with indefinite lives: |  |  |
| Purchased in-process research and development | 19581 | 12281 |
| Total intangible assets — net | $48737 | 37618 |

---

<sup>(1)</sup> The majority is comprised of customer relationships

Goodwill as of September 28, 2025 was allocated by segment of business as follows:

---

| | | | |
|:---|:---|:---|:---|
| **(Dollars in Millions)** | **Innovative**<br>**Medicine** | **MedTech** | **Total** |
| Goodwill at December 29, 2024 | $10692 | 33508 | 44200 |
| Goodwill, related to acquisitions | 2846 |  | 2846 |
| Goodwill, related to divestitures |  | (29) | (29) |
| Currency translation/Other | 730 | 301 | 1031 |
| Goodwill at September 28, 2025 | $14268 | 33780 | 48048 |

---

&nbsp;&nbsp;&nbsp;&nbsp;

The weighted average amortization period for patents and trademarks is approximately 13 years. The weighted average amortization period for customer relationships and other intangible assets is approximately 19 years. The amortization expense of amortizable intangible assets included in the cost of products sold was $1.0 billion and $1.2 billion for the fiscal third quarters ended September 28, 2025 and September 29, 2024, respectively. The amortization expense of amortizable intangible assets included in the cost of products sold was $3.4 billion for both the fiscal nine months ended September 28, 2025 and September 29, 2024, respectively.

The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **(Dollars in Millions)** | **(Dollars in Millions)** | | | |
| **2025** | **2026** | **2027** | **2028** | **2029** |
| $4500 | 4000 | 3300 | 2600 | 2500 |

---

See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.

Form 10-Q<sub>9</sub>

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

**Note 4 — Fair value measurements**

The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges.

Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities.

The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of September 28, 2025, the cumulative amount of cash collateral paid by the Company under the CSA amounted to $4.8 billion net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of September 28, 2025, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $45.2 billion, $39.6 billion and $8.0 billion, respectively. As of December 29, 2024, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $45.1 billion, $40.5 billion and $9.0 billion, respectively.

All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.

The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction.

Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued.

The Company designated its Euro denominated notes with due dates ranging from 2028 to 2055 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates.

As of September 28, 2025, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $0.3 billion after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and net investment hedge contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.

---

| | |
|:---|:---|
| **10** | ![Jhonson&Jhonson.jpg](jnj-20250928_g1.jpg) |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

The following table is a summary of the activity related to derivatives and hedges for the fiscal third quarters ended September 28, 2025 and September 29, 2024, net of tax:

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **September 28, 2025** | **September 28, 2025** | **September 28, 2025** | **September 28, 2025** | **September 28, 2025** | **September 29, 2024** | **September 29, 2024** | **September 29, 2024** | **September 29, 2024** | **September 29, 2024** |
|<br>**(Dollars in Millions)** | **Sales** | **Cost of**<br>**Products**<br>**Sold** | **R&D**<br>**Expense** | **Interest**<br>**(Income)**<br>**Expense** | **Other**<br>**(Income)**<br>**Expense** | **Sales** | **Cost of**<br>**Products**<br>**Sold** | **R&D**<br>**Expense** | **Interest**<br>**(Income)**<br>**Expense** | **Other**<br>**(Income)**<br>**Expense** |
| The effects of fair value, net investment and cash flow hedging: |  |  |  |  |  |  |  |  |  |  |
| **Gain (Loss) on fair value hedging relationship:** |  |  |  |  |  |  |  |  |  |  |
| **Interest rate swaps contracts:** |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Hedged items | $— |  |  | 130 |  |  |  |  | 343 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Derivatives designated as hedging instruments |  |  |  | (130) |  |  |  |  | (343) |  |
| **Gain (Loss) on net investment hedging relationship:** |  |  |  |  |  |  |  |  |  |  |
| **Cross currency interest rate swaps contracts:** |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing |  |  |  | 47 |  |  |  |  | 35 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Amount of gain or (loss) recognized in AOCI |  |  |  | 47 |  |  |  |  | 35 |  |
| **Gain (Loss) on cash flow hedging relationship:** |  |  |  |  |  |  |  |  |  |  |
| **Forward foreign exchange contracts:** |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Amount of gain or (loss) reclassified from AOCI into income | 1 | 19 | (21) |  | (10) | 1 | 44 |  |  | (4) |
| &nbsp;&nbsp;&nbsp;&nbsp;Amount of gain or (loss) recognized in AOCI | (6) | 100 | 2 |  |  |  | (30) | (21) |  | 1 |
| **Cross currency interest rate swaps contracts:** |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Amount of gain or (loss) reclassified from AOCI into income |  |  |  | 85 |  |  |  |  | 72 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Amount of gain or (loss) recognized in AOCI | $— |  |  | 291 |  |  |  |  | 420 |  |

---

Form 10-Q<sub>11</sub>

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

The following table is a summary of the activity related to derivatives and hedges for the fiscal nine months ended September 28, 2025 and September 29, 2024, net of tax:

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **September 28, 2025** | **September 28, 2025** | **September 28, 2025** | **September 28, 2025** | **September 28, 2025** | **September 29, 2024** | **September 29, 2024** | **September 29, 2024** | **September 29, 2024** | **September 29, 2024** |
|<br>**(Dollars in Millions)** | **Sales** | **Cost of Products Sold** | **R&D Expense** | **Interest (Income) Expense** | **Other (Income) Expense** | **Sales** | **Cost of Products Sold** | **R&D Expense** | **Interest (Income) Expense** | **Other (Income) Expense** |
| The effects of fair value, net investment and cash flow hedging: |  |  |  |  |  |  |  |  |  |  |
| **Gain (Loss) on fair value hedging relationship:** |  |  |  |  |  |  |  |  |  |  |
| **Interest rate swaps contracts:** |  |  |  |  |  |  |  |  |  |  |
| Hedged items | $— |  |  | 370 |  |  |  |  | 298 |  |
| Derivatives designated as hedging instruments |  |  |  | (370) |  |  |  |  | (298) |  |
| **Gain (Loss) on net investment hedging relationship:** |  |  |  |  |  |  |  |  |  |  |
| **Cross currency interest rate swaps contracts:** |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing |  |  |  | 145 |  |  |  |  | 102 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Amount of gain or (loss) recognized in AOCI |  |  |  | 145 |  |  |  |  | 102 |  |
| **Gain (Loss) on cash flow hedging relationship:** |  |  |  |  |  |  |  |  |  |  |
| **Forward foreign exchange contracts:** |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Amount of gain or (loss) reclassified from AOCI into income | 2 | (103) | (36) |  | (13) | 1 | 303 | 12 |  | (3) |
| &nbsp;&nbsp;&nbsp;&nbsp;Amount of gain or (loss) recognized in AOCI | 8 | 671 | (106) |  | (40) | (1) | 17 | 12 |  | 6 |
| **Cross currency interest rate swaps contracts:** |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Amount of gain or (loss) reclassified from AOCI into income |  |  |  | 243 |  |  |  |  | 162 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Amount of gain or (loss) recognized in AOCI | $— |  |  | 964 |  |  |  |  | 177 |  |

---

---

| | |
|:---|:---|
| **12** | ![Jhonson&Jhonson.jpg](jnj-20250928_g1.jpg) |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

As of September 28, 2025, and December 29, 2024, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Line item in the Consolidated Balance Sheet in which the hedged item is included** | **Carrying Amount of the Hedged Liability** | **Carrying Amount of the Hedged Liability** | **Cumulative Amount of Fair Value**<br>**Hedging Gain/ (Loss) Included in the**<br>**Carrying Amount of the Hedged Liability** | **Cumulative Amount of Fair Value**<br>**Hedging Gain/ (Loss) Included in the**<br>**Carrying Amount of the Hedged Liability** |
| **(Dollars in Millions)** | **September 28, 2025** | **December 29, 2024** | **September 28, 2025** | **December 29, 2024** |
| Long-term Debt | $8355 | 7935 | (652) | (1132) |

---

The following table is the effect of derivatives not designated as hedging instruments for the fiscal third quarters ended and fiscal nine months ended 2025 and 2024:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | | **Gain/(Loss)<br>Recognized In<br>Income on Derivative** | **Gain/(Loss)<br>Recognized In<br>Income on Derivative** | **Gain/(Loss)<br>Recognized In<br>Income on Derivative** | **Gain/(Loss)<br>Recognized In<br>Income on Derivative** |
|<br>**(Dollars in Millions)** |<br>**Location of<br>Gain /(Loss)<br>Recognized in<br>Income on Derivative** | **Fiscal Third Quarter Ended** | **Fiscal Third Quarter Ended** | **Fiscal Nine Months Ended** | **Fiscal Nine Months Ended** |
| Derivatives Not Designated as Hedging Instruments |  | **September 28, 2025** | **September 29, 2024** | **September 28, 2025** | **September 29, 2024** |
| Foreign Exchange Contracts | Other (income) expense | $33 | (21) | 76 | 24 |

---

The following table is the effect of net investment hedges for the fiscal third quarters ended in 2025 and 2024:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Gain/(Loss)**<br>**Recognized In**<br>**Accumulated OCI** | **Gain/(Loss)**<br>**Recognized In**<br>**Accumulated OCI** | **Location of Gain or (Loss)<br>Reclassified from Accumulated OCI Into Income** | **Gain/(Loss) Reclassified From<br>Accumulated OCI<br>Into Income** | **Gain/(Loss) Reclassified From<br>Accumulated OCI<br>Into Income** |
|<br>**(Dollars in Millions)** | **September 28, 2025** | **September 29, 2024** | | **September 28, 2025** | **September 29, 2024** |
| Debt | $— | (199) | Interest (income) expense |  |  |
| Cross Currency interest rate swaps | $123 | (251) | Interest (income) expense |  |  |

---

The following table is the effect of net investment hedges for the fiscal nine months ended in 2025 and 2024:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Gain/(Loss)<br>Recognized In<br>Accumulated OCI** | **Gain/(Loss)<br>Recognized In<br>Accumulated OCI** | **Location of Gain or (Loss)<br>Reclassified from Accumulated<br>OCI Into Income** | **Gain/(Loss) Reclassified From<br>Accumulated OCI<br>Into Income** | **Gain/(Loss) Reclassified From<br>Accumulated OCI<br>Into Income** |
|<br>**(Dollars in Millions)** | **September 28, 2025** | **September 29, 2024** | | **September 28, 2025** | **September 29, 2024** |
| Debt | $(1119) | (69) | Interest (income) expense |  |  |
| Cross Currency interest rate swaps | $264 | 569 | Interest (income) expense |  |  |

---

Form 10-Q<sub>13</sub>

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company has elected to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.

The following table is a summary of the activity related to equity investments:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **December 29, 2024** | | | **September 28, 2025** | **September 28, 2025** |
|<br>**(Dollars in Millions)** | **Carrying Value** |<br>**Changes in Fair Value Reflected in Net Income** <sup>(1)</sup> |<br>**(Sales)/ Purchases/Other** <sup>(2)</sup> | **Carrying Value** | **Non Current Other Assets** |
| Equity Investments with readily determinable value | $451 | 128 | (6) | 573 | 573 |
| Equity Investments without readily determinable value | $773 | 211 | (105) | 879 | 879 |

---

<sup>(1)</sup> Recorded in Other (income)/expense, net

<sup>(2)</sup> Other includes impact of currency

Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest.

The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company's results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.

The following three levels of inputs are used to measure fair value:

Level 1 — Quoted prices in active markets for identical assets and liabilities.

Level 2 — Significant other observable inputs.

Level 3 — Significant unobservable inputs.

---

| | |
|:---|:---|
| **14** | ![Jhonson&Jhonson.jpg](jnj-20250928_g1.jpg) |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

The Company's significant financial assets and liabilities measured at fair value as of September 28, 2025 and December 29, 2024 were as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **September 28, 2025** | **September 28, 2025** | **September 28, 2025** | **September 28, 2025** | **December 29, 2024** |
|<br>**(Dollars in Millions)** | **Level 1** | **Level 2** | **Level 3** | **Total** | **Total**<sup>(1)</sup> |
| **Derivatives designated as hedging instruments:** | | | | | |
| **Assets:** | | | | | |
| Forward foreign exchange contracts | $— | 815 |  | 815 | 660 |
| Interest rate contracts<sup>(2)</sup> |  | 589 |  | 589 | 1484 |
| **Total** |  | 1404 |  | 1404 | 2144 |
| **Liabilities:** |  |  |  |  |  |
| Forward foreign exchange contracts |  | 370 |  | 370 | 794 |
| Interest rate contracts<sup>(2)</sup>  |  | 5695 |  | 5695 | 3753 |
| **Total** |  | 6065 |  | 6065 | 4547 |
| **Derivatives not designated as hedging instruments:** |  |  |  |  |  |
| **Assets:** |  |  |  |  |  |
| Forward foreign exchange contracts |  | 41 |  | 41 | 50 |
| **Liabilities:** |  |  |  |  |  |
| Forward foreign exchange contracts |  | 28 |  | 28 | 17 |
| **Other Investments:** |  |  |  |  |  |
| Equity investments<sup>(3)</sup> | 573 |  |  | 573 | 451 |
| Debt securities<sup>(4)</sup> |  | 3825 |  | 3825 | 7216 |
| **Other Liabilities:** |  |  |  |  |  |
| Contingent consideration<sup>(5)</sup> | $— |  | 1110 | 1110 | 1217 |

---

---

| | | |
|:---|:---|:---|
| **Gross to Net Derivative Reconciliation** | **September 28, 2025** | **December 29, 2024** |
| **(Dollars in Millions)** | | |
| Total Gross Assets | $1445 | 2194 |
| Credit Support Agreement (CSA) | (1238) | (2172) |
| Total Net Asset | 207 | 22 |
| Total Gross Liabilities | 6093 | 4564 |
| Credit Support Agreement (CSA) | (6062) | (4412) |
| Total Net Liabilities | $31 | 152 |

---

Summarized information about changes in liabilities for contingent consideration for the fiscal third quarters ended September 28, 2025 and September 29, 2024 is as follows:

---

| | | |
|:---|:---|:---|
| | **September 28, 2025** | **September 29, 2024** |
| **(Dollars in Millions)** | | |
| Beginning Balance | $1217 | 1092 |
| Changes in estimated fair value<sup>(6)</sup>  | (57) | 93 |
| Additions |  | 112 |
| Payments | (50) | (75) |
| Ending Balance | $1110 | 1222 |

---

<sup>(1)</sup> 2024 assets and liabilities are all classified as Level 2 with the exception of equity investments of $451 million, which are classified as Level 1 and contingent consideration of $1,217 million, classified as Level 3.

<sup>(2)</sup> Includes cross currency interest rate swaps and interest rate swaps.

<sup>(3)</sup> Classified as non-current other assets.

---

| | |
|:---|:---|
| Form 10-Q | **15** |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

<sup>(4)</sup> Classified within cash equivalents and current marketable securities.

<sup>(5)</sup> Classified as non-current other liabilities.

<sup>(6)</sup> Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense.

The Company's cash, cash equivalents and current marketable securities as of September 28, 2025 comprised:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **(Dollars in Millions)** | **Carrying**<br>**Amount** | **Unrealized Gain** | **Estimated**<br>**Fair Value** | **Cash & Cash**<br>**Equivalents** | **Current**<br>**Marketable**<br>**Securities** |
| Cash | $3097 |  | 3097 | 3097 |  |
| U.S. reverse repurchase agreements | 5463 |  | 5463 | 5463 |  |
| Money market funds | 5298 |  | 5298 | 5298 |  |
| Time deposits<sup>(1)</sup> | 879 |  | 879 | 879 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Subtotal | 14737 |  | 14737 | 14737 |  |
| U.S. Gov't securities | 3368 |  | 3368 | 3354 | 14 |
| Other sovereign securities | 226 |  | 226 | 101 | 125 |
| Corporate debt securities | 231 |  | 231 | 39 | 192 |
| &nbsp;&nbsp;&nbsp;&nbsp;Subtotal available for sale debt<sup>(2)</sup> | $3825 |  | 3825 | 3494 | 331 |
| Total cash, cash equivalents and current marketable securities | $18562 |  | 18562 | 18231 | 331 |

---

<sup>(1)</sup> Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings.

<sup>(2)</sup> Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.

As of the fiscal year ended December 29, 2024, the carrying amount of cash, cash equivalents and current marketable securities was approximately the same as the estimated fair value.

Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and significant other observable inputs.

The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as current marketable securities.

The contractual maturities of the available for sale securities as of September 28, 2025 are as follows:

---

| | | |
|:---|:---|:---|
| **(Dollars in Millions)** | **Cost Basis** | **Fair Value** |
| Due within one year | $3806 | 3806 |
| Due after one year through five years | 19 | 19 |
| Due after five years through ten years |  |  |
| Total debt securities | $3825 | 3825 |

---

---

| | |
|:---|:---|
| **16** | ![Jhonson&Jhonson.jpg](jnj-20250928_g1.jpg) |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

**Financial instruments not measured at fair value**

The following financial liabilities are held at carrying amount on the consolidated balance sheet as of September 28, 2025:

---

| | | |
|:---|:---|:---|
| **(Dollars in Millions)** | **Carrying**<br>**Amount** | **Estimated**<br>**Fair Value** |
| **Financial Liabilities** | | |
| **Current Debt** | $6387 | 6373 |
| **Non-Current Debt** |  |  |
| 2.95% Notes due 2027 | 969 | 989 |
| 0.95% Notes due 2027 | 1498 | 1426 |
| 4.50% Notes due 2027<sup>(1)</sup> | 749 | 760 |
| 2.90% Notes due 2028 | 1498 | 1473 |
| 1.150% Notes due 2028 (750MM Euro 1.1704) | 875 | 848 |
| 4.55% Notes due 2028<sup>(1)</sup> | 748 | 764 |
| 4.80% Notes due 2029 | 1146 | 1185 |
| 6.95% Notes due 2029 | 299 | 333 |
| 2.70% Notes due 2029 (600MM Euro 1.1704)<sup>(1)</sup> | 701 | 707 |
| 1.30% Notes due 2030 | 1694 | 1546 |
| 4.70% Notes due 2030<sup>(1)</sup> | 996 | 1030 |
| 4.90% Notes due 2031 | 1146 | 1198 |
| 3.20% Notes due 2032 (700MM Euro 1.1704) | 816 | 832 |
| 4.85% Notes due 2032<sup>(1)</sup> | 1243 | 1297 |
| 4.95% Notes due 2033 | 499 | 521 |
| 4.375% Notes due 2033 | 853 | 859 |
| 3.050% Notes due 2033 (700MM Euro 1.1704)<sup>(1)</sup> | 817 | 822 |
| 4.95% Notes due 2034 | 847 | 892 |
| 1.650% Notes due 2035 (1.5B Euro 1.1704) | 1745 | 1525 |
| 5.00% Notes due 2035<sup>(1)</sup> | 1244 | 1297 |
| 3.35% Notes due 2036 (800MM Euro 1.1704) | 931 | 933 |
| 3.587% Notes due 2036 | 923 | 914 |
| 5.95% Notes due 2037 | 995 | 1116 |
| 3.625% Notes due 2037 | 1414 | 1359 |
| 3.350% Notes due 2037 (1.0B Euro 1.1704)<sup>(1)</sup> | 1168 | 1156 |
| 3.40% Notes due 2038 | 994 | 877 |
| 5.85% Notes due 2038 | 697 | 774 |
| 4.50% Notes due 2040 | 542 | 532 |
| 2.10% Notes due 2040 | 903 | 703 |
| 4.85% Notes due 2041 | 298 | 299 |
| 4.50% Notes due 2043 | 496 | 472 |
| 3.55% Notes due 2044 (1.0B Euro 1.1704) | 1160 | 1127 |
| 3.60% Notes due 2045 (700MM Euro 1.1704)<sup>(1)</sup> | 814 | 787 |
| 3.73% Notes due 2046 | 1979 | 1637 |
| 3.75% Notes due 2047 | 884 | 814 |
| 3.50% Notes due 2048 | 744 | 582 |
| 2.25% Notes due 2050 | 870 | 602 |
| 5.25% Notes due 2054 | 843 | 865 |

---

---

| | |
|:---|:---|
| Form 10-Q | **17** |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

---

| | | |
|:---|:---|:---|
| 3.70% Notes due 2055 (1.0B Euro 1.1704)<sup>(1)</sup> | 1164 | 1094 |
| 2.45% Notes due 2060 | 1120 | 709 |
| Other | 86 | 85 |
| Total Non-Current Debt | $39408 | 37741 |

---

<sup>(1)</sup> In the fiscal first quarter of 2025, the Company issued senior unsecured notes for approximately $9.2 billion. The net proceeds from this offering were used to fund the Intra-Cellular Therapies, Inc. acquisition which closed on April 2, 2025, and for general corporate purposes.

The weighted average effective interest rate on non-current debt is 3.56%.

The excess of the carrying value over the estimated fair value of debt was $2.0 billion at December 29, 2024.

Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.

The current debt balance as of September 28, 2025, includes $4.4 billion of commercial paper which has a weighted average interest rate of 4.10% and a weighted average maturity of approximately two months.

**Note 5 — Income taxes**

The worldwide effective income tax rates for the fiscal nine months of 2025 and 2024 were 21.5% and 16.9%, respectively.

The increase in the worldwide effective tax rate is primarily due to the United States enacting into law on July 4, 2025, the One Big Beautiful Bill Act (OBBBA). The OBBBA includes provisions modifying the corporate income tax code, including the immediate expensing of domestic research and development expenditures for tax purposes, 100% bonus depreciation for qualified assets, and an increase in the statutory tax rate on foreign earnings from 10.5% to 12.6%. The law also renamed the provision for taxes on foreign earnings from Global Intangible Low-Taxed Income (GILTI) to Net Controlled Foreign Corporation (CFC) Tested Income (NCTI). The Company has elected to account for GILTI, now NCTI, under the deferred method. As a result, in the fiscal third quarter the Company remeasured its deferred tax balances related to NCTI for the changes in the tax rate and recorded a one-time re-measurement cost of approximately $1.0 billion.

The Company's 2025 effective tax rate was also unfavorably impacted by more income in higher tax jurisdictions, specifically in the U.S. In the fiscal nine months of 2025, the Company reversed previously accrued reserves of approximately $7.0 billion for the Talc settlement proposal versus a charge of $5.1 billion recorded in the fiscal nine months of 2024 for the Talc settlement proposal. Both were recorded at an effective rate for U.S. federal and state tax of approximately 22% (for further information see Note 11 to the Consolidated Financial Statements). In the fiscal nine months of 2025, the effective tax rate had offsetting tax rate benefits primarily from changes in uncertain international tax positions due to expiration of statute of limitations.

As of September 28, 2025, the Company had approximately $2.2 billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the Internal Revenue Service has completed its audit for the tax years through 2016 and has commenced the audit for tax years 2017 through 2020.

In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2013. The Company believes it is possible that tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions outside of the United States.

---

| | |
|:---|:---|
| **18** | ![Jhonson&Jhonson.jpg](jnj-20250928_g1.jpg) |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

**Note 6 — Pensions and other benefit plans**

**Components of net periodic benefit cost**

Net periodic benefit costs for the Company's defined benefit retirement plans and other benefit plans include the following components:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Fiscal Third Quarter Ended** | **Fiscal Third Quarter Ended** | **Fiscal Third Quarter Ended** | **Fiscal Third Quarter Ended** | **Fiscal Nine Months Ended** | **Fiscal Nine Months Ended** | **Fiscal Nine Months Ended** | **Fiscal Nine Months Ended** |
| | **Retirement Plans** | **Retirement Plans** | **Other Benefit Plans** | **Other Benefit Plans** | **Retirement Plans** | **Retirement Plans** | **Other Benefit Plans** | **Other Benefit Plans** |
| **(Dollars in Millions)** | **September 28, 2025** | **September 29, 2024** | **September 28, 2025** | **September 29, 2024** | **September 28, 2025** | **September 29, 2024** | **September 28, 2025** | **September 29, 2024** |
| Service cost | $223 | 225 | 72 | 69 | 656 | 671 | 216 | 207 |
| Interest cost | 358 | 351 | 54 | 53 | 1065 | 1054 | 161 | 157 |
| Expected return on plan assets | (604) | (643) | (2) | (2) | (1790) | (1924) | (5) | (5) |
| Amortization of prior service cost/(credit) | (46) | (46) |  |  | (138) | (138) | (1) | (1) |
| Recognized actuarial (gains)/losses | 86 | 43 | 16 | 13 | 254 | 130 | 47 | 39 |
| Curtailments and settlements |  | 6 |  |  | 1 | (2) |  |  |
| Net periodic benefit cost/(credit) | $17 | (64) | 140 | 133 | 48 | (209) | 418 | 397 |

---

The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported, including Cost of products sold, Research and development expense, and Selling, marketing and administrative expenses. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings.

**Company contributions**

For the fiscal nine months ended September 28, 2025, the Company contributed $101 million and $11 million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.

---

| | |
|:---|:---|
| Form 10-Q | **19** |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

**Note 7 — Accumulated other comprehensive income**

Components of other comprehensive income/(loss) consist of the following:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **(Dollars in Millions)** | **Foreign**<br>**Currency**<br>**Translation** | **Gain/**<br>**(Loss) On**<br>**Securities** | **Employee**<br>**Benefit**<br>**Plans** | **Gain/**<br>**(Loss) On**<br>**Derivatives**<br>**& Hedges** | **Total**<br>**Accumulated**<br>**Other**<br>**Comprehensive**<br>**Income/(Loss)** |
| **(Dollars in Millions)** | **Foreign**<br>**Currency**<br>**Translation** | **Gain/**<br>**(Loss) On**<br>**Securities** | **Employee**<br>**Benefit**<br>**Plans** | **Gain/**<br>**(Loss) On**<br>**Derivatives**<br>**& Hedges** | **Total**<br>**Accumulated**<br>**Other**<br>**Comprehensive**<br>**Income/(Loss)** |
| December 29, 2024 | $(8441) | 1 | (1551) | (1750) | (11741) |
| Net change | (5031) | (1) | 132 | 1404 | (3496) |
| September 28, 2025 | (13472) | 0 | (1419) | (346) | (15237) |

---

Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income.

Details on reclassifications out of Accumulated Other Comprehensive Income:

Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.

Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 6 for additional details.

Gain/(Loss) On Derivatives & Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction. See Note 4 for additional details.

**Note 8 — Earnings per share**

The following is a reconciliation of basic net earnings per share to diluted net earnings per share:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Fiscal Third Quarter Ended** | **Fiscal Third Quarter Ended** | **Fiscal Nine Months Ended** | **Fiscal Nine Months Ended** |
|<br>**(Shares in Millions)** | **September 28, 2025** | **September 29, 2024** | **September 28, 2025** | **September 29, 2024** |
| Basic net earnings per share | $2.14 | 1.12 | 9.01 | 4.42 |
| Average shares outstanding — basic | 2408.3 | 2407.2 | 2407.3 | 2407.4 |
| Potential shares exercisable under stock option plans | 124.3 | 89.1 | 89.3 | 78.8 |
| Less: shares which could be repurchased under treasury stock method | (104.0) | (68.4) | (71.8) | (56.7) |
| Average shares outstanding — diluted | 2428.6 | 2427.9 | 2424.8 | 2429.5 |
| Diluted net earnings per share | $2.12 | 1.11 | 8.94 | 4.38 |
| **(Shares in Millions)** |  |  |  |  |
| &nbsp;&nbsp;The diluted net earnings per share calculation excluded the following number of shares related to stock options, as the exercise price of these options was greater than the average market value of the Company's stock. | 0.0 | 43.0 | 38.8 | 54.2 |

---

---

| | |
|:---|:---|
| **20** | ![Jhonson&Jhonson.jpg](jnj-20250928_g1.jpg) |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

**Note 9 — Segments of business and geographic areas**

The Company is organized into two business segments: Innovative Medicine and MedTech.

The Company's chief operating decision maker (CODM) is the Chief Executive Officer (Principal Executive Officer). For the Innovative Medicine and MedTech segments, the CODM uses segment income before tax to allocate resources (including employees, financial, and capital resources) for each segment predominantly in the annual forecasting process. The CODM considers planning-to-actual variances on a quarterly basis to assess performance and make decisions about allocating resources to the segments.

**Sales by segment of business**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Fiscal Third Quarter Ended** | **Fiscal Third Quarter Ended** | **Fiscal Third Quarter Ended** | **Fiscal Nine Months Ended** | **Fiscal Nine Months Ended** | **Fiscal Nine Months Ended** |
| **(Dollars in Millions)** | **September 28,<br>2025** | **September 29,<br>2024** | **Percent<br>Change** | **September 28,<br>2025** | **September 29,<br>2024** | **Percent**<br>**Change** |
| **INNOVATIVE MEDICINE** | | | | | | |
| **Oncology** | | | | | | |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | $3468 | 2816 | 23.2% | $9866 | 7835 | 25.9% |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 3060 | 2565 | 19.3 | 8652 | 7450 | 16.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide  | 6529 | 5380 | 21.3 | 18519 | 15284 | 21.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>CARVYKTI</u> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 396 | 258 | 53.3 | 1072 | 565 | 89.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 128 | 27 | \* | 260 | 63 | \* |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide | 524 | 286 | 83.5 | 1332 | 629 | \* |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>DARZALEX</u> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 2088 | 1684 | 24.0 | 5934 | 4789 | 23.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 1584 | 1332 | 18.9 | 4514 | 3797 | 18.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide | 3672 | 3016 | 21.7 | 10448 | 8586 | 21.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>ERLEADA</u> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 378 | 337 | 12.3 | 1048 | 940 | 11.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 558 | 453 | 23.0 | 1567 | 1275 | 22.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide | 936 | 790 | 18.4 | 2615 | 2215 | 18.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>IMBRUVICA</u> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 211 | 259 | (18.3) | 685 | 770 | (11.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 483 | 494 | (2.3) | 1453 | 1537 | (5.4) |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide  | 695 | 753 | (7.8) | 2139 | 2307 | (7.3) |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>RYBREVANT/ LAZCLUZE</u><sup>(1)</sup> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 136 | 68 | 99.7 | 388 | 156 | \* |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 61 | 21 | \* | 130 | 49 | \* |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide  | 198 | 89 | \* | 518 | 205 | \* |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>TALVEY</u> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 85 | 64 | 34.2 | 235 | 173 | 35.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 37 | 12 | \* | 79 | 29 | \* |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide  | 122 | 75 | 60.8 | 314 | 202 | 55.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>TECVAYLI</u> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 115 | 105 | 9.3 | 334 | 310 | 7.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 62 | 30 | \* | 160 | 93 | 73.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide  | 177 | 135 | 31.3 | 494 | 403 | 22.6 |

---

---

| | |
|:---|:---|
| Form 10-Q | **21** |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Fiscal Third Quarter Ended** | **Fiscal Third Quarter Ended** | **Fiscal Third Quarter Ended** | **Fiscal Nine Months Ended** | **Fiscal Nine Months Ended** | **Fiscal Nine Months Ended** |
| **(Dollars in Millions)** | **September 28,<br>2025** | **September 29,<br>2024** | **Percent<br>Change** | **September 28,<br>2025** | **September 29,<br>2024** | **Percent**<br>**Change** |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>ZYTIGA</u> / <u>abiraterone acetate</u> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 5 | 5 | (25.0) | 18 | 25 | (30.4) |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 108 | 144 | (25.1) | 365 | 470 | (22.3) |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide  | 113 | 150 | (25.1) | 383 | 496 | (22.8) |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>OTHER ONCOLOGY</u> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 56 | 36 | 54.6 | 153 | 106 | 44.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 39 | 50 | (22.2) | 123 | 136 | (9.7) |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide | 94 | 86 | 9.7 | 276 | 242 | 14.0 |
| **Immunology** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 2676 | 3068 | (12.8) | 7377 | 8499 | (13.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 1493 | 1552 | (3.9) | 4492 | 5090 | (11.8) |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide | 4168 | 4621 | (9.8) | 11868 | 13590 | (12.7) |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>REMICADE</u> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 326 | 281 | 16.2 | 923 | 778 | 18.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. Exports | 19 | 27 | (30.9) | 63 | 89 | (29.6) |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 132 | 112 | 17.7 | 413 | 380 | 8.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide  | 476 | 419 | 13.6 | 1398 | 1246 | 12.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>SIMPONI / SIMPONI ARIA</u> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 309 | 299 | 3.6 | 906 | 820 | 10.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 377 | 218 | 73.0 | 1130 | 787 | 43.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide  | 687 | 516 | 32.9 | 2036 | 1607 | 26.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>STELARA</u> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 1022 | 1770 | (42.3) | 3081 | 5021 | (38.6) |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 549 | 906 | (39.4) | 1768 | 2991 | (40.9) |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide  | 1570 | 2676 | (41.3) | 4848 | 8012 | (39.5) |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>TREMFYA</u> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 989 | 691 | 43.1 | 2384 | 1789 | 33.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 434 | 316 | 37.4 | 1181 | 932 | 26.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide  | 1424 | 1007 | 41.3 | 3566 | 2721 | 31.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>OTHER IMMUNOLOGY</u> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 12 | 1 | \* | 21 | 3 | \* |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 0 | 0 |  | 0 | 0 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide | 12 | 1 | \* | 21 | 3 | \* |
| **Neuroscience** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 1367 | 1094 | 25.0 | 3712 | 3250 | 14.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 658 | 662 | (0.7) | 2011 | 2090 | (3.8) |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide | 2024 | 1755 | 15.3 | 5722 | 5340 | 7.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>CAPLYTA</u><sup>(2)</sup> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 240 |  | \* | 451 |  | \* |
| &nbsp;&nbsp;&nbsp;&nbsp;International |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide  | 240 |  | \* | 451 |  | \* |

---

---

| | |
|:---|:---|
| **22** | ![Jhonson&Jhonson.jpg](jnj-20250928_g1.jpg) |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Fiscal Third Quarter Ended** | **Fiscal Third Quarter Ended** | **Fiscal Third Quarter Ended** | **Fiscal Nine Months Ended** | **Fiscal Nine Months Ended** | **Fiscal Nine Months Ended** |
| **(Dollars in Millions)** | **September 28,<br>2025** | **September 29,<br>2024** | **Percent<br>Change** | **September 28,<br>2025** | **September 29,<br>2024** | **Percent**<br>**Change** |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>CONCERTA / methylphenidate</u> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 14 | 26 | (49.2) | 76 | 101 | (24.9) |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 127 | 117 | 9.0 | 376 | 382 | (1.4) |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide  | 140 | 142 | (1.4) | 452 | 482 | (6.3) |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA</u> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 664 | 780 | (14.9) | 2021 | 2329 | (13.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 267 | 269 | (0.9) | 804 | 830 | (3.1) |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide  | 929 | 1049 | (11.3) | 2824 | 3159 | (10.6) |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>SPRAVATO</u> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 405 | 243 | 67.1 | 1047 | 660 | 58.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 53 | 42 | 28.9 | 146 | 120 | 21.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide | 459 | 284 | 61.5 | 1193 | 780 | 53.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>OTHER NEUROSCIENCE</u> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 46 | 46 | 0.4 | 119 | 161 | (26.4) |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 210 | 235 | (10.7) | 684 | 759 | (9.8) |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide | 256 | 281 | (8.9) | 803 | 920 | (12.7) |
| **Pulmonary Hypertension** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 815 | 815 | (0.1) | 2358 | 2324 | 1.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 300 | 287 | 4.8 | 895 | 866 | 3.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide  | 1115 | 1102 | 1.1 | 3253 | 3190 | 2.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>OPSUMIT/OPSYNVI</u> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 409 | 417 | (1.6) | 1175 | 1149 | 2.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 168 | 166 | 1.1 | 507 | 506 | 0.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide | 578 | 583 | (0.8) | 1682 | 1655 | 1.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>UPTRAVI</u> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 392 | 379 | 3.5 | 1139 | 1120 | 1.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 92 | 80 | 15.2 | 272 | 232 | 17.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide | 484 | 458 | 5.6 | 1411 | 1352 | 4.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>OTHER PULMONARY HYPERTENSION</u> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 13 | 21 | (36.5) | 44 | 56 | (21.5) |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 39 | 39 | (1.0) | 116 | 127 | (8.9) |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide | 53 | 60 | (13.1) | 160 | 183 | (12.7) |
| **Infectious Diseases** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 326 | 365 | (10.5) | 961 | 1023 | (6.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 501 | 471 | 6.4 | 1472 | 1599 | (7.9) |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide | 829 | 836 | (0.9) | 2434 | 2622 | (7.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>EDURANT / rilpivirine</u> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 7 | 8 | (7.9) | 21 | 24 | (11.8) |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 378 | 323 | 16.9 | 1082 | 926 | 16.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide | 385 | 330 | 16.4 | 1103 | 950 | 16.1 |

---

---

| | |
|:---|:---|
| Form 10-Q | **23** |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Fiscal Third Quarter Ended** | **Fiscal Third Quarter Ended** | **Fiscal Third Quarter Ended** | **Fiscal Nine Months Ended** | **Fiscal Nine Months Ended** | **Fiscal Nine Months Ended** |
| **(Dollars in Millions)** | **September 28,<br>2025** | **September 29,<br>2024** | **Percent<br>Change** | **September 28,<br>2025** | **September 29,<br>2024** | **Percent**<br>**Change** |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA</u> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 315 | 355 | (11.0) | 932 | 990 | (5.8) |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 81 | 94 | (13.6) | 264 | 315 | (16.1) |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide | 397 | 449 | (11.6) | 1196 | 1305 | (8.3) |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>OTHER INFECTIOUS DISEASES</u> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 4 | 3 | 57.3 | 8 | 10 | (11.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 42 | 54 | (21.2) | 126 | 358 | (64.7) |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide | 47 | 56 | (17.5) | 135 | 367 | (63.3) |
| **Cardiovascular / Metabolism / Other** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 750 | 713 | 5.3 | 2381 | 2061 | 15.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 149 | 170 | (13.1) | 461 | 543 | (15.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide | 899 | 884 | 1.7 | 2842 | 2605 | 9.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>XARELTO</u> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 635 | 592 | 7.4 | 1946 | 1697 | 14.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;International |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide | 635 | 592 | 7.4 | 1946 | 1697 | 14.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>OTHER</u> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 115 | 121 | (5.2) | 435 | 364 | 19.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 149 | 170 | (13.1) | 461 | 543 | (15.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide | 264 | 292 | (9.8) | 896 | 908 | (1.3) |
| **TOTAL INNOVATIVE MEDICINE** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 9402 | 8871 | 6.0 | 26655 | 24993 | 6.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 6161 | 5709 | 7.9 | 17983 | 17639 | 1.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide | 15563 | 14580 | 6.8 | 44638 | 42632 | 4.7 |
| **MEDTECH** |  |  |  |  |  |  |
| **Cardiovascular** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 1306 | 1148 | 13.8 | 3931 | 3292 | 19.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 908 | 819 | 10.8 | 2698 | 2353 | 14.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide | 2213 | 1966 | 12.6 | 6629 | 5645 | 17.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>ELECTROPHYSIOLOGY</u> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 720 | 660 | 9.1 | 2145 | 2057 | 4.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 698 | 619 | 12.6 | 2064 | 1889 | 9.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide | 1418 | 1279 | 10.8 | 4209 | 3946 | 6.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>ABIOMED</u> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 336 | 293 | 14.5 | 1035 | 905 | 14.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 86 | 68 | 26.8 | 256 | 207 | 23.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide | 423 | 362 | 16.8 | 1291 | 1112 | 16.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>SHOCKWAVE</u><sup>(3)</sup>  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 220 | 163 | 34.4 | 659 | 240 | \* |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 59 | 66 | (11.2) | 169 | 66 | \* |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide | 278 | 229 | 21.2 | 828 | 306 | \* |

---

---

| | |
|:---|:---|
| **24** | ![Jhonson&Jhonson.jpg](jnj-20250928_g1.jpg) |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Fiscal Third Quarter Ended** | **Fiscal Third Quarter Ended** | **Fiscal Third Quarter Ended** | **Fiscal Nine Months Ended** | **Fiscal Nine Months Ended** | **Fiscal Nine Months Ended** |
| **(Dollars in Millions)** | **September 28,<br>2025** | **September 29,<br>2024** | **Percent<br>Change** | **September 28,<br>2025** | **September 29,<br>2024** | **Percent**<br>**Change** |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>OTHER CARDIOVASCULAR</u> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 30 | 30 | 0.0 | 93 | 89 | 4.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 65 | 66 | (1.0) | 209 | 192 | 9.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide | 95 | 96 | (0.7) | 302 | 281 | 7.5 |
| **Orthopaedics** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 1396 | 1359 | 2.7 | 4200 | 4229 | (0.7) |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 878 | 832 | 5.6 | 2620 | 2614 | 0.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide | 2274 | 2191 | 3.8 | 6820 | 6843 | (0.3) |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>HIPS</u> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 262 | 250 | 4.7 | 796 | 785 | 1.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 144 | 131 | 9.7 | 440 | 435 | 1.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide | 405 | 381 | 6.4 | 1235 | 1220 | 1.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>KNEES</u> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 216 | 212 | 2.1 | 673 | 684 | (1.5) |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 160 | 140 | 14.3 | 482 | 463 | 4.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide | 377 | 352 | 7.0 | 1155 | 1147 | 0.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>TRAUMA</u> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 512 | 497 | 3.0 | 1515 | 1499 | 1.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 281 | 265 | 6.4 | 818 | 786 | 4.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide | 793 | 761 | 4.2 | 2333 | 2285 | 2.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>SPINE, SPORTS & OTHER</u> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 406 | 400 | 1.3 | 1216 | 1262 | (3.7) |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 293 | 296 | (1.1) | 881 | 930 | (5.3) |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide | 698 | 696 | 0.3 | 2096 | 2191 | (4.3) |
| **Surgery** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 1031 | 983 | 4.9 | 3076 | 2965 | 3.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 1511 | 1451 | 4.1 | 4417 | 4373 | 1.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide | 2542 | 2434 | 4.4 | 7493 | 7338 | 2.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>ADVANCED</u> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 477 | 448 | 6.2 | 1411 | 1360 | 3.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 688 | 661 | 4.2 | 1991 | 1977 | 0.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide | 1165 | 1109 | 5.0 | 3402 | 3337 | 1.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>GENERAL</u> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 555 | 535 | 3.8 | 1666 | 1605 | 3.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 823 | 791 | 4.0 | 2426 | 2397 | 1.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide | 1378 | 1325 | 3.9 | 4092 | 4001 | 2.3 |
| **Vision** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. | 571 | 549 | 4.2 | 1694 | 1619 | 4.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;International | 828 | 751 | 10.2 | 2354 | 2224 | 5.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Worldwide | 1400 | 1300 | 7.7 | 4048 | 3843 | 5.3 |

---

---

| | |
|:---|:---|
| Form 10-Q | **25** |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Fiscal Third Quarter Ended** | **Fiscal Third Quarter Ended** | **Fiscal Third Quarter Ended** | **Fiscal Nine Months Ended** | **Fiscal Nine Months Ended** | **Fiscal Nine Months Ended** |
| **(Dollars in Millions)** | **September 28,<br>2025** | **September 29,<br>2024** | **Percent<br>Change** | **September 28,<br>2025** | **September 29,<br>2024** | **Percent**<br>**Change** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>CONTACT LENSES / OTHER</u> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. | 456 | 441 | 3.5 | 1337 | 1288 | 3.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;International | 562 | 527 | 6.6 | 1565 | 1508 | 3.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Worldwide | 1018 | 968 | 5.2 | 2902 | 2796 | 3.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>SURGICAL</u> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. | 116 | 108 | 7.0 | 358 | 331 | 8.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;International | 266 | 225 | 18.7 | 789 | 717 | 10.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Worldwide | 383 | 333 | 14.9 | 1147 | 1048 | 9.4 |
| **TOTAL MEDTECH** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 4306 | 4038 | 6.6 | 12902 | 12105 | 6.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 4124 | 3853 | 7.0 | 12089 | 11564 | 4.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide | 8430 | 7891 | 6.8 | 24991 | 23669 | 5.6 |
| **WORLDWIDE** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 13708 | 12909 | 6.2 | 39557 | 37098 | 6.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 10285 | 9562 | 7.6 | 30072 | 29203 | 3.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Worldwide | $23993 | 22471 | 6.8% | $69629 | 66301 | 5.0% |

---

\*&nbsp;&nbsp;&nbsp;&nbsp;Percentage greater than 100% or not meaningful

<sup>(1)</sup> Includes the sales of RYBREVANT and RYBREVANT + LAZCLUZE

<sup>(2)</sup> Acquired with the Intra-Cellular Therapies acquisition on April 2, 2025 

<sup>(3)</sup> Due to the timing of the integration of the US and foreign affiliates in the year of acquisition (2024), prior quarter (Q3 2024) Shockwave International revenue includes approximately $20 million of sales that should be reflected in the U.S. business. Year-to-date and total Shockwave sales are not impacted, and the amount was immaterial to recast prior year reporting

Subsequent to the quarter, on October 14, 2025, the Company announced its intention to separate its Orthopaedics business. The Company intends to explore multiple paths to effect the planned separation with a targeted completion within 18 to 24 months after the initial announcement.

---

| | |
|:---|:---|
| **26** | ![Jhonson&Jhonson.jpg](jnj-20250928_g1.jpg) |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

**Segment income before tax**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Fiscal Third Quarter Ended** | **Fiscal Third Quarter Ended** | **Fiscal Third Quarter Ended** | **Fiscal Third Quarter Ended** | **Fiscal Third Quarter Ended** | **Fiscal Third Quarter Ended** |
| **(Dollars in Millions)** | **September 28,<br>2025** | **September 28,<br>2025** | **September 28,<br>2025** | **September 29,<br>2024** | **September 29,<br>2024** | **September 29,<br>2024** |
|  | Innovative Medicine<sup>(1)</sup> | MedTech<sup>(2)</sup> | Total | Innovative Medicine<sup>(1)</sup> | MedTech<sup>(2)</sup> | Total |
| Sales to customers | $15563 | 8430 |  | 14580 | 7891 |  |
| Cost of products sold | 3672 | 3612 |  | 3549 | 3381 |  |
| Selling, marketing and administrative | 2869 | 2801 |  | 2491 | 2723 |  |
| Research and development expense | 2944 | 728 |  | 4213 | 739 |  |
| Other segment items <sup>(3)</sup> | (368) | 2 |  | (155) | (11) |  |
| Segment income before tax | $6446 | 1287 | 7733 | 4482 | 1059 | 5541 |
| (Income)/Expense not allocated to segments <sup>(4)</sup> |  |  | 240 |  |  | 2203 |
| Earnings before provision for taxes on income |  |  | $7493 |  |  | $3338 |
|  | **Fiscal Nine Months Ended** | **Fiscal Nine Months Ended** | **Fiscal Nine Months Ended** | **Fiscal Nine Months Ended** | **Fiscal Nine Months Ended** | **Fiscal Nine Months Ended** |
| Sales to customers | $44638 | 24991 |  | 42632 | 23669 |  |
| Cost of products sold | 11670 | 10576 |  | 10522 | 9749 |  |
| Selling, marketing and administrative | 7919 | 8319 |  | 7594 | 7976 |  |
| Research and development expense | 8361 | 2052 |  | 9831 | 2103 |  |
| Other segment items <sup>(3)</sup> | (520) | 132 |  | (225) | 173 |  |
| Segment income before tax | $17208 | 3912 | 21120 | 14910 | 3668 | 18578 |
| (Income)/Expense not allocated to segments <sup>(4)</sup> |  |  | (6495) |  |  | 5778 |
| Earnings before provision for taxes on income |  |  | $27615 |  |  | $12800 |

---

<sup>(1)</sup> Innovative Medicine includes:

&nbsp;&nbsp;&nbsp;&nbsp;**•** Intangible amortization expense of $0.6 billion and $0.7 billion in the fiscal third quarter of 2025 and 2024, respectively. Intangible amortization expense of $2.0 billion and $2.1 billion in the fiscal nine months of 2025 and 2024, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;**•** Acquisition and integration related expense of $0.1 billion and $0.3 billion in the fiscal third quarter and fiscal nine months of 2025, respectively, primarily related to the Intra-Cellular acquisition.

&nbsp;&nbsp;&nbsp;&nbsp;• Expense of $1.25 billion to secure the global rights to the NM26 bispecific antibody (Yellow Jersey acquisition) in the fiscal third quarter and fiscal nine months of 2024.

&nbsp;&nbsp;&nbsp;&nbsp;• Litigation expense of $0.4 billion in both the fiscal third quarter and fiscal nine months of 2024, primarily related to Risperdal Gynecomastia.

&nbsp;&nbsp;&nbsp;&nbsp;• Monetization of royalty rights of $0.3 billion in the fiscal third quarter and fiscal nine months of 2024.

&nbsp;&nbsp;&nbsp;&nbsp;• An In-process research and development impairment of $0.2 billion in the fiscal nine months of 2024 associated with the M710 (biosimilar) asset acquired from Momenta in 2020.

&nbsp;&nbsp;&nbsp;&nbsp;• A restructuring related charge of $0.1 billion in the fiscal nine months of 2024.

<sup>(2)&nbsp;&nbsp;&nbsp;&nbsp;</sup>MedTech includes:

&nbsp;&nbsp;&nbsp;&nbsp;**•** Intangible amortization expense of $0.5 billion in both the fiscal third quarter of 2025 and 2024. Intangible amortization expense of $1.4 billion and $1.3 billion in the fiscal nine months of 2025 and 2024, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;**•** Acquisition and integration related net expense of $0.1 billion and $0.2 billion in the fiscal third quarter and fiscal nine months of 2025, respectively. Acquisition and integration related expense of $0.3 billion and $0.9 billion, in the fiscal third quarter and fiscal nine months of 2024, respectively, primarily driven by the Shockwave acquisition.

&nbsp;&nbsp;&nbsp;&nbsp;• A gain on the sale of securities of $0.2 billion in the fiscal third quarter and fiscal nine months of 2025

&nbsp;&nbsp;&nbsp;&nbsp;**•** A gain of $0.2 billion related to the Acclarent divestiture in the fiscal nine months of 2024.

&nbsp;&nbsp;&nbsp;&nbsp;**•** A restructuring related charge of $0.2 billion and $0.3 billion in both the fiscal third quarter and fiscal nine months of 2025. A restructuring related charge of $0.1 billion in the fiscal nine months of 2024. Refer to Note 12 for additional details.

---

| | |
|:---|:---|
| Form 10-Q | **27** |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

<sup>(3)</sup> <sup>&nbsp;&nbsp;&nbsp;&nbsp;</sup>Other segment expenses for each reportable segment include charges related to other income and expense, restructuring activities and impairment charges related to in-process research and development.

<sup>(4)</sup> Amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. The fiscal nine months of 2025 includes the reversal of approximately $7.0 billion, a significant portion of the previously accrued talc reserve. The fiscal third quarter and fiscal nine months of 2024 includes charges for talc matters of $2.0 billion and $5.1 billion, respectively. For additional details related to talc refer to Note 11 to the Consolidated Financial Statements. The fiscal nine months of 2024 includes a loss of approximately $0.4 billion related to the debt to equity exchange of the Company's remaining shares of Kenvue Common Stock.

---

| | | |
|:---|:---|:---|
| | **Identifiable Assets** | **Identifiable Assets** |
|<br>**(Dollars in Millions)** | **September 28, 2025** | **December 29, 2024** |
| Innovative Medicine | $74422 | 57070 |
| MedTech | 86502 | 84322 |
| **Total** | 160924 | 141392 |
| General corporate <sup>(1)</sup> | 31892 | 38712 |
| **Worldwide total** | **$192816** | **180104** |

---

<sup>(1)</sup> General corporate includes cash, cash equivalents, marketable securities and other corporate assets.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Additions to Property,<br>Plant & Equipment** | **Additions to Property,<br>Plant & Equipment** | **Depreciation and<br>Amortization** | **Depreciation and<br>Amortization** |
| | **Fiscal Nine Months Ended** | **Fiscal Nine Months Ended** | **Fiscal Nine Months Ended** | **Fiscal Nine Months Ended** |
|<br>**(Dollars in Millions)** | **September 28, 2025** | **September 29, 2024** | **September 28, 2025** | **September 29, 2024** |
| Innovative Medicine | $1166 | 971 | $2757 | 2793 |
| MedTech | 1674 | 1629 | 2564 | 2370 |
| Segments total | 2840 | 2600 | 5321 | 5163 |
| General corporate | 155 | 212 | 171 | 280 |
| **Worldwide total** | **$2995** | **2812** | **$5492** | **5443** |

---

**Sales by geographic area**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Fiscal Third Quarter Ended** | **Fiscal Third Quarter Ended** | **Fiscal Third Quarter Ended** | **Fiscal Nine Months Ended** | **Fiscal Nine Months Ended** | **Fiscal Nine Months Ended** |
|<br>**(Dollars in Millions)** | **September 28, 2025** | **September 29, 2024** | **Percent<br>Change** | **September 28, 2025** | **September 29, 2024** | **Percent Change** |
| United States | $13708 | 12909 | 6.2% | $39557 | 37098 | 6.6% |
| Europe | 5440 | 4914 | 10.7 | 15937 | 15291 | 4.2 |
| Western Hemisphere, excluding U.S. | 1231 | 1173 | 4.9 | 3604 | 3579 | 0.7 |
| Asia-Pacific, Africa | 3614 | 3475 | 4.0 | 10531 | 10333 | 1.9 |
| **Total** | $23993 | 22471 | 6.8% | $69629 | 66301 | 5.0% |

---

---

| | |
|:---|:---|
| **28** | ![Jhonson&Jhonson.jpg](jnj-20250928_g1.jpg) |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

**Note 10 — Acquisitions and divestitures**

**Business combinations**

**2025 Transactions**

On April 2, 2025, the Company completed the acquisition of Intra-Cellular Therapies, Inc. (Intra-Cellular), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders. This acquisition advances the Company's industry-leading portfolio in mental health with the addition of CAPLYTA (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive therapy and monotherapy and is also approved for the treatment of schizophrenia in adults. Further, an sNDA has been submitted to the U.S. FDA for CAPLYTA as adjunctive treatment for major depressive disorder. This acquisition also includes a promising clinical-stage pipeline with best-in-class potential in generalized anxiety disorder and Alzheimer's disease-related psychosis and agitation.

The Company acquired all the outstanding shares of Intra-Cellular's common stock for $132.00 per share in an all-cash merger transaction for total consideration transferred of $14.5 billion. The acquisition was accounted for as a business combination and the results of operations and goodwill are included in the Innovative Medicine segment as of the acquisition date. In addition, acquisition-related costs before tax incurred during the fiscal nine months of 2025 were $0.3 billion, of which $0.1 billion related to post-closing compensation expense due to the acceleration of equity awards and were recorded to Other (income) expense, net.

The following table summarizes the preliminary fair value of assets acquired and liabilities assumed as of the acquisition date and is based on the best estimate of management, which is subject to change within the measurement period. As of the fiscal quarter ended September 28, 2025, there have been no material measurement period adjustments.

---

| | |
|:---|:---|
| (Dollars in Billions) | **April 2, 2025** |
| **Assets acquired:** |  |
| Cash and cash equivalents | $0.2 |
| Marketable securities | 0.6 |
| Other current & non-current assets | 0.3 |
| Amortizable intangible asset <sup>(1)</sup> | 5.2 |
| Acquired in-process research and development <sup>(1)</sup> | 8.3 |
| Goodwill <sup>(2)</sup> | 2.9 |
| Total assets acquired | $17.5 |
| **Liabilities assumed:** |  |
| Deferred taxes | $2.8 |
| Other current & non-current liabilities | 0.2 |
| Total liabilities assumed | $3.0 |
| Total assets acquired and liabilities assumed | $14.5 |

---

<sup>(1)</sup> The estimated fair values of the intangible assets acquired were determined using the multi-period excess earnings method. The amortizable intangible asset relates to the currently marketed product, CAPLYTA, which has an estimated useful life of 8 years. The acquired in-process research and development includes two assets, one related to certain unapproved indications of lumateperone and another related to a compound being studied to treat psychosis and agitation in patients with Alzheimer's disease and generalized anxiety disorder. The fair value of the in-process research and development assets were calculated assuming a discount rate of 11.5% and 12.5%, respectively. Additionally, the cash flow projections assumed a probability of success factor of 95% and approximately 34%-50% (depending on indication being studied), respectively.

<sup>(2)</sup> Goodwill is primarily attributable to intangible assets that did not qualify for separate recognition and future projects or products currently unidentified. Goodwill is not expected to be deductible for tax purposes.

**2024 Transactions**

On June 20, 2024, the Company completed the acquisition of Proteologix, Inc., a privately held biotechnology company focused on bispecific antibodies for immune-mediated diseases, in an all-cash merger transaction for total consideration of $0.8 billion net of cash acquired, with potential for an additional milestone payment. The results of operations were included in the Innovative Medicine segment as of the acquisition date. The fair value of the acquisition was allocated to assets acquired of $1.2 billion,

---

| | |
|:---|:---|
| Form 10-Q | **29** |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

primarily non-amortizable intangible assets, inclusive of purchased in-process-research and development (IPR&D), for $0.9 billion, goodwill for $0.3 billion, and liabilities assumed of $0.3 billion, including $0.1 billion of contingent consideration. The goodwill is not deductible for tax purposes. Acquisition related costs before tax for the fiscal nine months of 2025 are not material.

On May 31, 2024, the Company acquired all the outstanding shares of Shockwave Medical Inc. (SWAV), a leading, first-to-market provider of innovative intravascular lithotripsy (IVL) technology for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD), in an all-cash merger transaction for total consideration of $12.6 billion, ($11.5 billion, net of cash acquired). The results of operations were included in the MedTech segment as of the acquisition date. The fair value of the acquisition was allocated to assets acquired of $14.4 billion primarily amortizable intangible assets of $5.3 billion, purchased IPR&D of $0.6 billion, goodwill for $7.6 billion, $0.5 billion of inventory and $0.4 billion of other assets, and liabilities assumed of $2.9 billion. The goodwill is not deductible for tax purposes. Acquisition related costs before tax were not material for the fiscal nine months of 2025 and were $0.7 billion for the fiscal nine months of 2024.

On March 7, 2024, the Company completed the acquisition of Ambrx Biopharma, Inc., (Ambrx), a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash merger transaction for a total consideration of approximately $1.8 billion net of cash acquired. The results of operations were included in the Innovative Medicine segment as of the acquisition date. The fair value of the acquisition was allocated to assets acquired of $2.3 billion, primarily non-amortizable intangible assets, inclusive of purchased IPR&D, for $1.9 billion, goodwill for $0.3 billion and liabilities assumed of $0.5 billion. The goodwill is not deductible for tax purposes. Acquisition related costs before tax for the fiscal nine months of 2025 and 2024 were not material.

**Asset acquisitions**

There were no material asset acquisitions in the fiscal nine months of 2025.

On July 11, 2024, the Company completed the acquisition of Yellow Jersey, a demerged subsidiary of Numab Therapeutics AG, to secure the global rights to NM26, a novel, investigational first-in-class bispecific antibody targeting two clinically proven pathways in atopic dermatitis (AD), in an all-cash transaction for approximately $1.25 billion. The Company recorded an in-process research and development IPR&D charge of approximately $1.25 billion, and the results of operations are included in the Innovative Medicine segment as of the acquisition date.

**Divestitures**

There were no material divestitures in the fiscal nine months of 2025.

In the fiscal nine months of 2024, the Company completed the divestitures of Acclarent resulting in approximately $0.3 billion in proceeds and the divestiture of Ponvory outside of the U.S. resulting in approximately $0.2 billion in proceeds.

---

| | |
|:---|:---|
| **30** | ![Jhonson&Jhonson.jpg](jnj-20250928_g1.jpg) |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

**Note 11 — Legal proceedings**

Johnson & Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business.

The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of September 28, 2025, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.

In the Company's opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company's balance sheet, is not expected to have a material adverse effect on the Company's financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company's results of operations and cash flows for that period.

**Matters concerning talc**

A significant number of personal injury claims alleging that talc causes cancer have been asserted against the Company and its affiliates arising out of the use of body powders containing talc, primarily JOHNSON'S Baby Powder.

In talc cases that have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $4.7 billion in Ingham v. Johnson & Johnson, et al., No. ED 207476 (Mo. App.), reducing the overall award to $2.1 billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied, and in June 2021, a petition for certiorari, seeking a review of the Ingham decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $2.5 billion. The facts and circumstances, including the terms of the award, were unique to the Ingham decision and not representative of other claims brought against the Company. The Company continues to believe that it has strong legal grounds to contest all the talc verdicts that it has appealed. Notwithstanding the Company's confidence in the safety of its talc products, in certain circumstances the Company has settled cases.

In an effort to expeditiously resolve the litigation for the overwhelming majority of claimants, beginning in October 2021, Johnson & Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring, through which Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtor's direct parent, Johnson & Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCI's assets and became solely responsible for the talc-related liabilities of Old JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers' compensation statute or act (the Talc-Related Liabilities).

Following the 2021 Corporate Restructuring, Debtor and the Company attempted to achieve a full and comprehensive resolution of the Talc-Related Liabilities. Debtor filed voluntary petitions for Bankruptcy pursuant to Chapter 11 of the Bankruptcy Code in October 2021 and again in April 2023; both petitions were dismissed.

In October 2023, the Company stated that it was pursuing the following four parallel and alternative pathways to achieve a comprehensive and final resolution of the talc claims: (i) the appeal of the LTL 2 dismissal decision; (ii) pursuing a consensual "prepackaged" bankruptcy case, as "strongly encouraged" by the Bankruptcy Court in its dismissal decision; (iii) aggressively

---

| | |
|:---|:---|
| Form 10-Q | **31** |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

litigating the talc claims in the tort system; and (iv) pursuing affirmative claims against experts for false and defamatory narratives regarding the Company's talc powder products. In December 2023, LTL changed its state of formation to Texas and its name to LLT Management LLC (LLT).

In May 2024, the Company commenced a three-month solicitation period of its proposed consensual "prepackaged" Chapter 11 bankruptcy plan (the Proposed Plan) for the comprehensive and final resolution of all current and future claims related to cosmetic talc in the United States, excluding claims related to mesothelioma or State consumer protection claims, in exchange for the payment by the Company of present value of approximately $6.475 billion payable over 25 years (nominal value of approximately $8.0 billion, discounted at a rate of 4.4%). The claims encompassed by the Proposed Plan constituted 99.75% of then-pending lawsuits against the Company relating to its talc powder products.

In August 2024, LLT engaged in a restructuring that resulted in the creation of three new Texas limited liability companies: (a) Red River Talc, LLC (Red River); (b) Pecos River Talc LLC (Pecos River); and (3) New Holdco (Texas) LLC. As a result of this restructuring, all claims related to ovarian and other gynecological cancers were separated and allocated to Red River, and mesothelioma, governmental unit and certain other claims were allocated to Pecos River.

While the Company had resolved 95% of the mesothelioma lawsuits filed to date as of August 2024, cases continue to be filed. Trial activity has continued in various state courts.

In September 2024, while reiterating the Company's continued confidence in the safety of its talc products, Red River filed a voluntary petition with the United States Bankruptcy Court for the Southern District of Texas, seeking relief under Chapter 11 of the Bankruptcy Code (the Red River Bankruptcy Case), in furtherance of the Company's consensual "prepackaged" Proposed Plan. Shortly thereafter, as a consequence of this filing, the Company withdrew its appeal of the LTL 2 dismissal decision.

To account for the contemplated comprehensive resolution through the Proposed Plan, the Company recorded a cumulative incremental charge of approximately $5.0 billion during fiscal year 2024. As of the end of fiscal year 2024, the total present value of the reserve was approximately $11.6 billion (or nominal value of approximately $13.5 billion).

On March 31, 2025, the Texas Bankruptcy Court issued an order dismissing the case (the Texas dismissal) and, as a result, the Company reversed substantially all, or approximately $7 billion, from amounts previously reserved for the bankruptcy resolution. As of the third quarter 2025, the total present value of the reserve is approximately $3.8 billion, comprising previously executed settlement agreements, litigation defense and other costs. Approximately one-third of the reserve is recorded as a current liability.

After the Texas dismissal, the Company announced it would not appeal the decision and returned to the tort system to litigate the talc claims and defend the safety of its products. Courts have been holding scheduling conferences and the Company is preparing to start bellwether trials in consolidated proceedings in the California JCCP in November 2025 and in the New Jersey MCL in January 2026. Additionally, ovarian cancer trials are being scheduled in various state courts throughout 2026 and beyond. In the MDL, the Court is addressing the Company's Daubert motions, which are expected to be decided by the first quarter of 2026.

In February 2019, the Company's talc supplier, Imerys Talc America, Inc., and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys), filed a voluntary petition for relief under Chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy) seeking indemnification from the Company and rights to joint insurance proceeds.

In February 2021, Cyprus Mines Corporation (Cyprus), which had owned certain Imerys talc mines, filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code in the Delaware Bankruptcy Court and filed its Disclosure Statement and Plan (the Cyprus Plan) also asserting claims for indemnity against the Company arising out of personal injury claims.

In July 2024, the Company, Imerys, and Cyprus and certain of their affiliates (including their parent entities), and the tort claimants' committees and future claimants' representatives appointed in the Imerys debtors' and Cyprus debtors' respective Chapter 11 cases entered into a global settlement agreement (the Imerys Settlement Agreement) to resolve the parties' ongoing disputes, including disputes raised in the Imerys and Cyprus bankruptcies. In October 2024, the Delaware Bankruptcy Court entered an order approving the Imerys Settlement Agreement (the Settlement Order).

Certain insurers have appealed the Settlement Order and sought a stay of the Settlement Order pending appeal, which the Delaware Bankruptcy Court denied in January 2025. The insurers then sought a stay of the Settlement Order in the District Court for the District of Delaware, which also was denied. The insurers then appealed the denial of their request for a stay of the Settlement Order to the Third Circuit Court of Appeals. In August 2025, the District Court denied the insurers' appeal of the Settlement Order. The insurers have appealed that decision to the Third Circuit. Both appeals are pending.

In January 2025, Imerys and Cyprus each filed a certification of voting results, indicating that their respective Chapter 11 plans had been accepted by each voting class of talc claimants. A joint confirmation hearing for the plans began in April 2025 but was continued, at the request of Imerys and Cyprus, after issues arose relating to treatment of foreign claims under their respective

---

| | |
|:---|:---|
| **32** | ![Jhonson&Jhonson.jpg](jnj-20250928_g1.jpg) |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

Chapter 11 plans. Imerys and Cyprus have since filed revised plans. The confirmation hearing is scheduled to continue the week of February 2, 2026.

In February 2018, a securities class action lawsuit was filed against the Company and certain named officers in the United States District Court for the District of New Jersey, alleging that the Company violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON'S Baby Powder, and that purchasers of the Company's shares suffered losses as a result. In April 2019, the Company moved to dismiss the complaint. In December 2019, the Court denied, in part, the motion to dismiss. In December 2023, the Court granted Plaintiff's motion for class certification. In January 2024, Defendants filed a petition with the Third Circuit under Federal Rule of Civil Procedure 23(f) for permission to appeal the Court's order granting class certification, and in February 2024, the Third Circuit granted Defendants' petition. In February 2024, fact discovery closed, the Court ordered the parties to mediate, and stayed the case pending mediation. In May 2024, the parties participated in an unsuccessful mediation. In June 2024, at the parties' request, the Court lifted the stay for certain limited discovery, but otherwise kept the stay in place pending a decision from the Third Circuit on the 23(f) petition. Briefing on the 23(f) petition was completed in September 2024, and in March 2025, the Third Circuit heard oral argument. In July 2025, the Third Circuit affirmed the Court's order granting class certification. In September 2025, Defendants petitioned the Third Circuit for rehearing or rehearing en banc, which was denied in October 2025.

**Matters concerning opioids**

Beginning in 2014 and continuing to the present, the Company and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in close to 3,500 lawsuits related to the marketing of opioids, including DURAGESIC, NUCYNTA and NUCYNTA ER. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children born with Neonatal Abstinence Syndrome (NAS); hospitals; and health insurers/payors.

To date, the Company and JPI have litigated two of the cases to judgment and have prevailed in both, either at trial or on appeal.

In July 2021, the Company announced finalization of an agreement to settle the state and subdivision claims for up to $5.0 billion. Approximately 80% of the all-in settlement was paid by the end of fiscal third quarter 2025. A few government entities opted out of the settlement. In September 2024, the Company reached an agreement to resolve the hospital cases.

The Company and JPI continue to defend the cases brought by the remaining government entity litigants as well as the cases brought by private litigants. In total, there are approximately 23 remaining opioid cases against the Company and JPI in various state courts, 285 remaining cases in the Ohio multi-district litigation (MDL), and 3 additional cases in other federal courts.

In addition, the Province of British Columbia filed suit against the Company and its Canadian affiliate, Janssen Inc., and many other industry members, in Canada. That action was certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada in January 2025. The defendants, including the Company, filed appeals from the certification order in late February 2025. That appeal is scheduled to be heard in December 2025. A common issues trial has been scheduled in 2028. Additional proposed class actions have been filed in Canada against the Company and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands. The proposed class action in Quebec on behalf of residents diagnosed with opioid use disorder was authorized to proceed against Janssen Inc. and other industry members in April 2024; and leave to appeal was denied in October 2024.

Starting in November 2019, a series of shareholder derivative complaints were filed against the Company as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that the Company has suffered damages as a result of those alleged breaches. As of September 2024, all the complaints had been dismissed, and all appeals exhausted.

**Product liability**

The Company and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25, Contingencies. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in

---

| | |
|:---|:---|
| Form 10-Q | **33** |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.

The table below contains the most significant of these cases and provides the approximate number of plaintiffs in the United States with direct claims in pending lawsuits regarding injuries allegedly due to the relevant product or product category as of September 28, 2025.

---

| | |
|:---|:---|
| **Product or product category** | **Number of plaintiffs**  |
| Body powders containing talc, primarily JOHNSON'S Baby Powder | 73570 |
| DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System | 40 |
| PINNACLE Acetabular Cup System | 780 |
| Pelvic meshes | 5220 |
| ETHICON PHYSIOMESH Flexible Composite Mesh | 110 |
| ELMIRON | 810 |

---

The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed. There may be additional claims that have not yet been filed.

**MedTech**

**DePuy ASR XL Acetabular System and ASR Hip Resurfacing System** 

In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and the Company. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Ireland, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.

**DePuy PINNACLE Acetabular Cup System**

Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and the Company (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Most cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas (Texas MDL). Beginning on June 1, 2022, the Judicial Panel on Multidistrict Litigation ceased transfer of new cases into the Texas MDL, and there are now cases pending in federal court outside the Texas MDL. Litigation also has been filed in state courts and in countries outside of the United States. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.

**Ethicon Pelvic Mesh** 

Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company arising out of Ethicon's pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company's accruals. In addition, class actions and individual personal injury cases or claims seeking damages for alleged injury resulting from Ethicon's pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, and Ireland, and class actions in Israel, Australia,

---

| | |
|:---|:---|
| **34** | ![Jhonson&Jhonson.jpg](jnj-20250928_g1.jpg) |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

Canada and South Africa. The vast majority of these actions are now resolved. The Company has established accruals with respect to product liability litigation associated with Ethicon's pelvic mesh products.

**Ethicon Physiomesh** 

Following a June 2016 worldwide market withdrawal of Ethicon Physiomesh Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. Other than a small number of cases still pending in the MDL, all Physiomesh matters in the United States have been resolved or are undergoing formal review for purposes of settlement.

Claims have also been filed against Ethicon and the Company alleging personal injuries arising from the PROCEED Mesh and PROCEED Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the United States, and in jurisdictions outside the United States.

Ethicon and the Company also have been subject to claims for personal injuries arising from the PROLENE Polypropylene Hernia System. In January 2020, the New Jersey Supreme Court created an MCL in Atlantic County Superior Court to handle such cases. Cases involving this product have also been filed in other federal and state courts in the United States.

In October 2022, an agreement in principle, subject to various conditions, was reached to settle the majority of the pending cases involving Proceed, Proceed Ventral Patch, Prolene Hernia System and related multi-layered mesh products, as well as a number of unfiled claims. All litigation activities in the two New Jersey MCLs are stayed pending effectuation of the proposed settlement. Future cases that are filed in the New Jersey MCLs will be subject to docket control orders requiring early expert reports and discovery requirements.

The Company has established accruals with respect to product liability litigation associated with Ethicon Physiomesh Flexible Composite Mesh, PROCEED Mesh and PROCEED Ventral Patch, and PROLENE Polypropylene Hernia System products.

**Innovative Medicine**

**ELMIRON** 

Claims for personal injury have been made against a number of Johnson & Johnson companies, including Janssen Pharmaceuticals, Inc. and the Company, arising out of the use of ELMIRON, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey (MDL). In addition, cases have been filed in various state courts of New Jersey, which have been coordinated in a multi-county litigation in Bergen County, as well as the Court of Common Pleas in Philadelphia, which have been coordinated and granted mass tort designation. In addition, three class action lawsuits have been filed in Canada. The Company continues to defend ELMIRON product liability lawsuits and continues to evaluate potential costs related to those claims. All U.S. based ELMIRON matters have been resolved or are undergoing formal review for purposes of settlement. The Company has established accruals for defense and indemnity costs associated with ELMIRON related product liability litigation.

**Intellectual property**

Certain subsidiaries of the Company are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the scope and/or validity of patents that relate to various products and allegations that certain of the Company's products infringe the intellectual property rights of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market

---

| | |
|:---|:---|
| Form 10-Q | **35** |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset.

**Innovative Medicine - litigation against filers of abbreviated new drug applications (ANDAs)**

The Company's subsidiaries have brought lawsuits against generic companies that have filed ANDAs with the U.S. FDA (or similar lawsuits outside of the United States) seeking to market generic versions of products sold by various subsidiaries of the Company prior to expiration of the applicable patents covering those products. These lawsuits typically include allegations of non-infringement and/or invalidity of patents listed in FDA's publication "Approved Drug Products with Therapeutic Equivalence Evaluations" (commonly known as the Orange Book). In each of these lawsuits, the Company's subsidiaries are seeking an order enjoining the defendant from marketing a generic version of a product before the expiration of the relevant patents (Orange Book Listed Patents). In the event the Company's subsidiaries are not successful in an action, or any automatic statutory stay expires before the court rulings are obtained, the generic companies involved would have the ability, upon regulatory approval, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Company's subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents.

The Inter Partes Review (IPR) process with the United States Patent and Trademark Office (USPTO), created under the 2011 America Invents Act, is also being used at times by generic companies in conjunction with ANDAs and lawsuits to challenge the applicable patents.

**XARELTO** 

Beginning in March 2021, Janssen Pharmaceuticals, Inc., Bayer Pharma AG, Bayer AG and Bayer Intellectual Property GmbH filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of XARELTO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Dr. Reddy's Laboratories, Inc.; Dr. Reddy's Laboratories, Ltd.; Lupin Limited; Lupin Pharmaceuticals, Inc.; Taro Pharmaceutical Industries Ltd.; Taro Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; Mylan Pharmaceuticals Inc.; Mylan Inc.; Mankind Pharma Limited; Apotex Inc.; Apotex Corp.; Cipla Ltd.; Cipla USA Inc.; InvaGen Pharmaceuticals, Inc.; and Prinston Pharmaceuticals, Inc. The following U.S. patents are included in one or more cases: 9,539,218 and 10,828,310. In July 2025, Bayer Intellectual Property GmbH, Bayer AG, Janssen Pharmaceuticals, Inc., and Mankind Pharma Limited filed a stipulation agreeing to dismiss the lawsuit against Mankind Pharma Limited, and the case was dismissed.

U.S. Patent No. 10,828,310 was also under consideration by the USPTO in an IPR proceeding. In July 2023, the USPTO issued a final written decision finding the claims of the patent invalid. In September 2023, Bayer Pharma AG filed an appeal to the U.S. Court of Appeals for the Federal Circuit. In September 2025, the Federal Circuit entered a decision affirming-in-part, vacating-in-part, and remanding for further proceedings.

**INVEGA SUSTENNA**

Beginning in January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Teva Pharmaceuticals USA, Inc.; Mylan Laboratories Limited; Pharmascience Inc.; Mallinckrodt PLC; Specgx LLC; Tolmar, Inc.; Accord Healthcare, Inc.; Qilu Pharmaceutical Co. Ltd.; Qilu Pharma Inc.; Sun Pharmaceutical Industries Ltd.; and Sun Pharmaceutical Industries, Inc. The following U.S. patent is included in one or more cases: 9,439,906. In October 2020, the district court issued a decision in the case against Teva Pharmaceuticals USA, Inc., finding that United States Patent No. 9,439,906 is not invalid. Teva previously stipulated to infringement. Teva appealed the decision, and, in April 2024, the United States Court of Appeals for the Federal Circuit vacated and remanded the case to the district court for further proceedings. In November 2024, the district court issued its decision on remand, finding that United States Patent No. 9,439,906 is not invalid. Teva appealed to the Court of Appeals for the Federal Circuit, and oral argument took place in April 2025. In July 2025, the Federal Circuit affirmed the district court ruling of no invalidity. The Mylan case was consolidated with the Teva case for purposes of appeal and the July ruling applies to Mylan. In February 2024, the district court issued a decision in the case against Tolmar Inc. finding that United States Patent No. 9,439,906 is not invalid. Tolmar previously stipulated to infringement of a subset of the claims, and based on a claim construction ruling, the district court entered a non-infringement order with respect to the remaining asserted claims. Tolmar has appealed the validity decision, and Janssen appealed the non-infringement decision.

Beginning in February 2018, Janssen Inc. and Janssen Pharmaceutica NV initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who have filed ANDSs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the listed patent. The following entities are named defendants: Pharmascience Inc. and Apotex Inc. The following Canadian patent is included in one or more cases: 2,655,335. In June 2024, the

---

| | |
|:---|:---|
| **36** | ![Jhonson&Jhonson.jpg](jnj-20250928_g1.jpg) |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

Supreme Court dismissed the Apotex case. In September 2024, the Supreme Court granted Pharmascience's motion to appeal the Federal Court's decision that the 2,655,335 Patent is not invalid.

**ERLEADA** 

In January 2025, Aragon Pharmaceuticals, Inc., Janssen Inc., (collectively, Janssen Inc.) and Sloan-Kettering Institute for Cancer Research (SKI) initiated Statements of Claims under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in response to Sandoz's filing of an ANDS seeking approval to market a generic version of ERLEADA before the expiration of CA Patent Nos. 3,008,345 (the '345 patent), 2,875,767 (the '767 patent), 2,885,415 (the '415 patent), and 3,128,331 (the '331 patent). Janssen Inc. and SKI are seeking an order enjoining Sandoz from marketing a generic version of ERLEADA before the expiration of the relevant patents.

Beginning in April 2025, Aragon Pharmaceuticals, Inc., Janssen Biotech, Inc., The Regents of the University of California, and Sloan-Kettering Institute for Cancer Research variously initiated patent infringement lawsuits in U.S. District Court for the District of New Jersey against generic manufacturers who have filed ANDAs seeking approval to market generic versions of ERLEADA before the expiration of certain Orange Book Listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; Hetero Labs Limited Unit V; and Hetero USA, Inc. The following U.S. patents are included in one or more cases: 8,445,507; 8,802,689; 9,338,159; 9,987,261; 9,481,663; 9,884,054; RE49,353; 10,849,888; 10,702,508; and 11,963,952. Aragon Pharmaceuticals, Inc., Janssen Biotech, Inc. and the Lupin parties entered into a confidential settlement in August 2025, and the case was dismissed.

**SPRAVATO** 

Beginning in May 2023, Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica NV filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SPRAVATO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Sandoz Inc.; Hikma Pharmaceuticals Inc. USA; Hikma Pharmaceuticals PLC; and Alkem Laboratories Ltd. The following U.S. patents are included in one or more cases: 10,869,844; 11,173,134; 11,311,500; and 11,446,260.

**CAPLYTA** 

Beginning in March 2024, Intra-Cellular Therapies, Inc. (Intra-Cellular) filed patent infringement lawsuits in the United States District Court for the District of New Jersey against generic manufacturers who have filed ANDAs seeking approval to market generic versions of CAPLYTA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Alkem Laboratories Ltd., Dr. Reddy's Laboratories Inc., Dr. Reddy's Laboratories Ltd., Hetero USA, Inc., Hetero Labs Ltd. Unit-V, Hetero Labs Ltd., MSN Laboratories Private Ltd., Zydus Pharmaceuticals (USA) Inc., and Zydus Lifesciences Ltd. The following U.S. Patents are included in one or more cases: US RE 48,825; RE 48,839; 8,648,077; 9,168,258; 9,199,995; 9,616,061; 9,956,227; 10,117,867; 10,464,938; 10,960,009; 11,026,951; 11,753,419; 11,980,617; 12,070,459; 12,090,155; 12,122,792; and 12,128,043. In July 2025, Intra-Cellular, Hetero USA, Inc., Hetero Labs Ltd. Unit-V, and Hetero Labs Ltd. entered into a confidential settlement agreement, and the case was dismissed.

**UPTRAVI** 

Beginning in September 2025, Actelion Pharmaceuticals Ltd, Actelion Pharmaceuticals US, Inc. and Nippon Shinyaku Co. Ltd. filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against generic manufacturers who have filed ANDAs seeking approval to market generic versions of UPTRAVI before expiration of certain Orange Book Listed Patents. The following entities are named defendants: VGYAAN Pharmaceuticals LLC, and RK Pharma, Inc. The following patent is included in the case: 7,205,302.

**MedTech** 

In March 2016, Abiomed, Inc. filed a declaratory judgment action against Maquet Cardiovascular LLC (Maquet) in the U.S. District Court for the District of Massachusetts seeking a declaration that certain Impella products do not infringe Maquet patents, including U.S. Patent Nos. 7,022,100 ('100 patent); 8,888,728; and 9,327,068. Maquet counterclaimed for infringement of those patents against Abiomed, Inc., Abiomed Europe GmbH, and Abiomed R&D, Inc. (collectively, Abiomed), and later added claims for infringement of U.S. Patent Nos. 9,545,468; 9,561,314; and 9,597,437. After claim construction, Maquet alleged infringement of only the '100 patent. In September 2021, the court granted Abiomed's motion for summary judgment of non-infringement of the '100 patent and, in September 2023, the district court entered final judgment in favor of Abiomed on all patents-in-suit. Maquet appealed.

In November 2017, Maquet Cardiovascular LLC filed suit against Abiomed, Inc., Abiomed R&D, Inc., and Abiomed Europe GmbH (collectively, Abiomed) in the U.S. District Court for the District of Massachusetts, alleging that certain Impella products infringe U.S. Patent No. 9,789,238 ('238 patent). Maquet subsequently added U.S. Patent No. 10,238,783 ('783 patent). After claim

---

| | |
|:---|:---|
| Form 10-Q | **37** |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

construction, the court entered a stipulated judgment of non-infringement of both patents. Maquet appealed. On March 21, 2025, the U.S. Court of Appeals for the Federal Circuit left undisturbed the judgment on non-infringement of the '238 patent, vacated the judgment regarding the '783 patent, and remanded the case to the District Court for further proceedings on the '783 patent.

**Government proceedings**

Like other companies in the pharmaceutical and medical technologies industries, the Company and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.

**MedTech** 

In July 2023, the DOJ issued Civil Investigative Demands to the Company, Johnson & Johnson Surgical Vision, Inc., and Johnson & Johnson Vision Care, Inc. (collectively, J&J Vision) in connection with a civil investigation under the False Claims Act relating to free or discounted intraocular lenses and equipment used in eye surgery, such as phacoemulsification and laser systems. J&J Vision has provided documents and information responsive to the Civil Investigative Demands and is continuing to cooperate with the DOJ regarding its inquiry.

**Innovative Medicine** 

In July 2016, the Company and Janssen Products, LP were served with a qui tam complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA and INTELENCE, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators. The Court denied summary judgment on all claims in December 2021. Daubert motions were granted in part and denied in part in January 2022, and trial commenced in May 2024. On June 13, 2024, a jury found no liability regarding the anti-kickback violations but found liability for a portion of the off-label promotion claims. The Company is pursuing post-trial briefing challenging the verdict on the off-label claims. On March 28, 2025, the Court granted in part and denied in part Janssen's motions and the Company is appealing the verdict and judgments. The Company filed a notice of appeal with the Third Circuit on April 29, 2025. Briefing is ongoing.

In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE or SIMPONI ARIA. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a qui tam False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the qui tam lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway.

**General litigation**

The Company or its subsidiaries are also parties to various proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local or foreign laws in which the primary relief sought is the Company's agreement to implement remediation activities at designated hazardous waste sites or to reimburse the government or third parties for the costs they have incurred in performing remediation at such sites.

In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson & Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2022, the United States Court of Appeals for the District of Columbia Circuit reversed the District Court's decision. In June 2023, defendants filed a petition for a writ of certiorari to the United States Supreme Court. In June 2024, the Supreme Court vacated the D.C. Circuit's decision and remanded the case to the D.C. Circuit. Oral argument was held in November 2024.

In February 2024, a putative class action was filed against the Company and the Pension & Benefits Committee of Johnson & Johnson (Committee) in United States District Court for the District of New Jersey. The complaint alleges that defendants breached fiduciary duties under the Employee Retirement Income Security Act (ERISA) by allegedly mismanaging the Company's prescription-drug benefits program. The complaint seeks damages and other relief. In January 2025, the Court granted in part and

---

| | |
|:---|:---|
| **38** | ![Jhonson&Jhonson.jpg](jnj-20250928_g1.jpg) |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

denied in part defendants' motion to dismiss, with leave to replead. In March 2025, plaintiffs filed a second amended complaint. In April 2025, defendants filed a motion to dismiss plaintiffs' fiduciary duty claims.

**MedTech** 

In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against the Company, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicon's acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants' motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. The trial occurred in January 2024. In September 2024, the court found liability with respect to certain claims and no liability with respect to other claims. In October 2025, oral argument occurred on the Company's appeal to the Delaware Supreme Court.

In October 2019, Innovative Health, LLC filed a complaint against Biosense Webster, Inc. (BWI) in the United States District Court for the Central District of California. The complaint alleges that certain of BWI's business practices and contractual terms violate the antitrust laws of the United States and the State of California by restricting competition in the sale of High Density Mapping Catheters and Ultrasound Catheters. In May 2025, a jury returned its verdict in favor of Innovative Health. In August 2025, the court issued a permanent injunction concerning BWI's business practices. BWI appealed both the jury verdict and the permanent injunction.

**Innovative Medicine**

In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc. and Actelion Clinical Research, Inc. (collectively, Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER. TRACLEER is subject to a Risk Evaluation and Mitigation Strategy required by the U.S. Food and Drug Administration, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland. In September 2024, the district court granted plaintiffs' motion for class certification. Trial is scheduled for March 2026.

In December 2023, a putative class action lawsuit was filed against the Company and Janssen Biotech Inc. (collectively, Janssen) in the United States District Court for the Eastern District of Virginia. The complaint alleges that Janssen violated federal and state antitrust laws and other state laws by delaying biosimilar competition with STELARA through Janssen's enforcement of patent rights covering STELARA. The complaint seeks damages and other relief. In February 2024, plaintiffs filed an amended complaint, which Janssen moved to dismiss in March 2024. In August 2024, the court granted in part and denied in part Janssen's motion to dismiss.

In December 2018, Janssen Biotech, Inc., Janssen Oncology, Inc., Janssen Research & Development, LLC and Johnson & Johnson (collectively, Janssen) were served with a qui tam complaint on behalf of the United States, certain states, and the District of Columbia. The complaint alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA to the government in connection with direct sales and reimbursement programs. At this time, the federal and state governments have declined to intervene. In December 2021, the United States District Court for the District of New Jersey denied Janssen's motion to dismiss.

---

| | |
|:---|:---|
| Form 10-Q | **39** |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

**Note 12 — Restructuring**

In fiscal 2025, the company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting certain non-strategic product lines and optimize select sites across the network. The pre-tax restructuring expense in the fiscal third quarter and fiscal nine months of 2025 primarily included costs related to asset impairments as well as market and product exits. The estimated costs of the total program are between $0.9 billion - $1.0 billion and is expected to be substantially completed by the end of fiscal year 2026.

In fiscal 2023, the Company initiated a restructuring program of its Orthopaedics franchise within its MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The pre-tax restructuring expense in the fiscal third quarter and fiscal nine months of 2025 primarily included costs related to asset impairments as well as market and product exits. The pre-tax restructuring expense in the fiscal third quarter and fiscal nine months of 2024 primarily included market and product exits. Total project costs of approximately $0.6 billion have been recorded since the restructuring was announced. The estimated costs of the total program are between $0.7 billion - $0.8 billion and will be substantially completed by the end of fiscal year 2025.

The following table summarizes the restructuring expenses for 2025 and 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **(Pre-tax Dollars in Millions)** | **Q3 2025** | **Q3 2024** | **Q3 YTD 2025** | **Q3 YTD 2024** |
| MedTech Segment Surgery franchise<sup>(1)</sup> | $128 |  | 157 |  |
| MedTech Segment Orthopaedics franchise<sup>(2)</sup> | 40 | 28 | 145 | 107 |
| Innovative Medicine Segment<sup>(3)</sup> |  | 19 |  | 100 |
| Total Programs | $168 | 47 | 302 | 207 |

---

<sup>(1)</sup> Included $35 million in Restructuring and $93 million in Other income and expense on the Consolidated Statement of Earnings in the fiscal third quarter of 2025. Included $64 million in Restructuring and $93 million in Other income and expense on the Consolidated Statement of Earnings in the fiscal nine months of 2025.

<sup>(2)</sup> Included $28 million in Restructuring and $12 million in Cost of products sold on the Consolidated Statement of Earnings in the fiscal third quarter of 2025. Included $80 million in Restructuring, $35 million in Cost of products sold and $30 million in Other (Income)/Expense on the Consolidated Statement of Earnings in the fiscal nine months of 2025. Included $22 million in Restructuring and $6 million in Cost of products sold on the Consolidated Statement of Earnings in the fiscal third quarter of 2024. Included $92 million in Restructuring and $15 million in Cost of products sold on the Consolidated Statement of Earnings in the fiscal nine months of 2024.

<sup>(3)</sup> Included in Restructuring on the Consolidated Statement of Earnings. This program was completed in the fiscal fourth quarter of 2024.

Restructuring reserves as of September 28, 2025 and December 29, 2024 were insignificant.

---

| | |
|:---|:---|
| **40** | ![Jhonson&Jhonson.jpg](jnj-20250928_g1.jpg) |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

**Item 2 — Management's discussion and analysis of financial condition and results of operations**

**Results of operations**

**Sales to customers**

**Analysis of consolidated sales**

For the fiscal nine months of 2025, worldwide sales were $69.6 billion, a total increase of 5.0%, including an operational\* increase of 4.7% as compared to 2024 fiscal nine months sales of $66.3 billion. Currency fluctuations had a positive impact of 0.3% for the fiscal nine months of 2025. In the fiscal nine months of 2025, acquisitions and divestitures had net positive impact of 1.2%, on worldwide operational sales growth, primarily related to CAPLYTA and Shockwave. In the fiscal nine months of 2025, the negative impact of the STELARA sales decline, due to biosimilar competition, on worldwide operational sales was approximately 6.1%.

Sales by U.S. companies were $39.6 billion in the fiscal nine months of 2025, which represented an increase of 6.6% as compared to the prior year. In the fiscal nine months of 2025, acquisitions and divestitures had net positive impact of 2.0% on U.S. operational sales growth, primarily related to CAPLYTA and Shockwave. In the fiscal nine months of 2025, the negative impact of the STELARA sales decline, due to biosimilar competition on U.S. operational sales was approximately 7.1%. Sales by international companies were $30.1 billion, which represented an increase of 3.0%, including an operational increase of 2.3%, and a positive currency impact of 0.7% as compared to the fiscal nine months sales of 2024. In the fiscal nine months of 2025, the net impact of acquisitions and divestitures on international operational sales growth was a positive 0.1%. In the fiscal nine months of 2025, the negative impact of the STELARA sales decline, due to biosimilar competition, on international operational sales was approximately 5.0%.

In the fiscal nine months of 2025, sales by companies in Europe achieved growth of 4.2%, which included an operational increase of 1.5% and a positive currency impact of 2.7%. Sales by companies in the Western Hemisphere, excluding the U.S., achieved growth of 0.7%, which included an operational increase of 7.6% partially offset by negative currency impact of 6.9%. Sales by companies in the Asia-Pacific, Africa region achieved growth of 1.9%, including operational growth of 1.8% and a positive currency impact of 0.1%.

**Fiscal nine months 2025 sales by geographic region (in billions)**

![2065](jnj-20250928_g2.jpg)

**Fiscal nine months 2025 sales by segment (in billions)**

![2121](jnj-20250928_g3.jpg)

Note: values may have been rounded

\*operational growth excludes the effect of translational currency

---

| | |
|:---|:---|
| Form 10-Q | **41** |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

For the fiscal third quarter of 2025, worldwide sales were $24.0 billion, a total increase of 6.8%, which included operational growth of 5.4% and a positive currency impact of 1.4% as compared to 2024 fiscal third quarter sales of $22.5 billion. In the fiscal third quarter of 2025, the net impact of acquisitions and divestitures on worldwide operational sales growth was a positive 1.0%, related to CAPLYTA. In the fiscal third quarter of 2025, the negative impact of the STELARA sales decline, due to biosimilar competition, on worldwide operational sales was approximately 6.4%.

Sales by U.S. companies were $13.7 billion in the fiscal third quarter of 2025, which represented an increase of 6.2% as compared to the prior year. In the fiscal third quarter of 2025, the net impact of acquisitions and divestitures on U.S. operational sales growth was a positive 1.8%. In the fiscal third quarter of 2025, the negative impact of the STELARA sales decline, due to biosimilar competition on U.S. operational sales was approximately 7.7%. Sales by international companies were $10.3 billion, a total increase of 7.6%, which included operational growth of 4.4% and a positive currency impact of 3.2%. In the fiscal third quarter of 2025, there was no net impact of acquisitions and divestitures on international operational sales growth. In the fiscal third quarter of 2025, the negative impact of the STELARA sales decline, due to biosimilar competition, on international operational sales was approximately 4.8%.

In the fiscal third quarter of 2025, sales by companies in Europe achieved growth of 10.7%, which included operational growth of 4.4% and a positive currency impact of 6.3%. Sales by companies in the Western Hemisphere, excluding the U.S., achieved growth of 4.9%, which included operational growth of 7.3% partially offset by a negative currency impact of 2.4%. Sales by companies in the Asia-Pacific, Africa region achieved growth of 4.0%, which included operational growth of 3.4% and a positive currency impact of 0.6%.

**Q3 2025 Sales by Geographic Region (in billions)**

![4182](jnj-20250928_g4.jpg)

**Q3 2025 Sales by Segment (in billions)**

![4223](jnj-20250928_g5.jpg)

Note: values may have been rounded

---

| | |
|:---|:---|
| **42** | ![Jhonson&Jhonson.jpg](jnj-20250928_g1.jpg) |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

**Analysis of sales by business segments**

**Innovative Medicine**

Innovative Medicine segment sales in the fiscal nine months of 2025 were $44.6 billion, an increase of 4.7% as compared to the same period a year ago, with an operational increase of 4.5% and a positive currency impact of 0.2%. U.S. Innovative Medicine sales increased 6.7% as compared to the same period a year ago. International Innovative Medicine sales increased by 1.9%, including an operational increase of 1.3% and a positive currency impact of 0.6%. In the fiscal nine months of 2025, the net impact of acquisitions and divestitures on the Innovative Medicine segment operational sales growth was a positive 1.1%, primarily related to CAPLYTA. In the fiscal nine months of 2025, the negative impact of the STELARA sales decline, due to biosimilar competition, was an approximate 10.1%, 11.3% and 8.7% on worldwide, U.S. and international Innovative Medicine segment operational sales, respectively.

**Major Innovative Medicine therapeutic area sales — Fiscal Nine Months Ended**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **(Dollars in Millions)** | **September 28, 2025** | **September 29, 2024** | **Total<br>Change** | **Operations<br>Change** | **Currency<br>Change** |
| **Oncology** | **$18519** | **$15284** | **21.2%** | **20.6%** | **0.6%** |
| &nbsp;&nbsp;&nbsp;&nbsp;CARVYKTI | 1332 | 629 | \* | \* | \* |
| &nbsp;&nbsp;&nbsp;&nbsp;DARZALEX | 10448 | 8586 | 21.7 | 21.3 | 0.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;ERLEADA | 2615 | 2215 | 18.0 | 17.0 | 1.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;IMBRUVICA | 2139 | 2307 | (7.3) | (7.9) | 0.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;RYBREVANT/ LAZCLUZE<sup>(1)</sup> | 518 | 205 | \* | \* | \* |
| &nbsp;&nbsp;&nbsp;&nbsp;TALVEY | 314 | 202 | 55.3 | 54.9 | 0.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;TECVAYLI | 494 | 403 | 22.6 | 22.5 | 0.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;ZYTIGA/ abiraterone acetate | 383 | 496 | (22.8) | (23.4) | 0.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other Oncology | 276 | 242 | 14.0 | 13.6 | 0.4 |
| **Immunology** | **11868** | **13590** | **(12.7)** | **(12.6)** | **(0.1)** |
| &nbsp;&nbsp;&nbsp;&nbsp;REMICADE | 1398 | 1246 | 12.2 | 12.7 | (0.5) |
| &nbsp;&nbsp;&nbsp;&nbsp;SIMPONI/ SIMPONI ARIA | 2036 | 1607 | 26.7 | 27.2 | (0.5) |
| &nbsp;&nbsp;&nbsp;&nbsp;STELARA | 4848 | 8012 | (39.5) | (39.5) | 0.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;TREMFYA | 3566 | 2721 | 31.0 | 30.8 | 0.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other Immunology | 21 | 3 | \* | \* |  |
| **Neuroscience** | **5722** | **5340** | **7.2** | **7.2** | **0.0** |
| &nbsp;&nbsp;&nbsp;&nbsp;CAPLYTA<sup>(2)</sup> | 451 |  | \* | \* |  |
| &nbsp;&nbsp;&nbsp;&nbsp;CONCERTA/methylphenidate | 452 | 482 | (6.3) | (5.5) | (0.8) |
| &nbsp;&nbsp;&nbsp;&nbsp;INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA | 2824 | 3159 | (10.6) | (10.5) | (0.1) |
| &nbsp;&nbsp;&nbsp;&nbsp;SPRAVATO | 1193 | 780 | 53.0 | 52.9 | 0.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other Neuroscience | 803 | 920 | (12.7) | (12.8) | 0.1 |
| **Pulmonary Hypertension** | **3253** | **3190** | **2.0** | **1.8** | **0.2** |
| &nbsp;&nbsp;&nbsp;&nbsp;OPSUMIT/ OPSYNVI | 1682 | 1655 | 1.7 | 1.4 | 0.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;UPTRAVI | 1411 | 1352 | 4.3 | 4.2 | 0.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other Pulmonary Hypertension | 160 | 183 | (12.7) | (12.9) | 0.2 |
| **Infectious Diseases** | **2434** | **2622** | **(7.2)** | **(8.3)** | **1.1** |
| &nbsp;&nbsp;&nbsp;&nbsp;EDURANT/rilpivirine | 1103 | 950 | 16.1 | 13.0 | 3.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;PREZISTA/ PREZCOBIX/ REZOLSTA/ SYMTUZA | 1196 | 1305 | (8.3) | (8.4) | 0.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other Infectious Diseases<sup>(3)</sup> | 135 | 367 | (63.3) | (63.2) | (0.1) |
| **Cardiovascular / Metabolism / Other** | **2842** | **2605** | **9.1** | **9.2** | **(0.1)** |
| &nbsp;&nbsp;&nbsp;&nbsp;XARELTO | 1946 | 1697 | 14.7 | 14.7 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | 896 | 908 | (1.3) | (1.0) | (0.3) |
| **Total Innovative Medicine Sales** | **$44638** | **$42632** | **4.7%** | **4.5%** | **0.2%** |

---

---

| | |
|:---|:---|
| Form 10-Q | **43** |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

\*percentage greater than 100% or not meaningful

<sup>(1)</sup> Includes the sales of RYBREVANT and RYBREVANT + LAZCLUZE

<sup>(2)</sup> Acquired with Intra-Cellular Therapies on April 2, 2025

<sup>(3)</sup> Includes the Covid-19 Vaccine in 2024

Innovative Medicine segment sales in the fiscal third quarter of 2025 were $15.6 billion, an increase of 6.8% as compared to the same period a year ago, including an operational increase of 5.3% and a positive currency impact of 1.5%. U.S. Innovative Medicine sales increased 6.0% as compared to the same period a year ago. International Innovative Medicine sales increased by 7.9%, including an operational increase of 4.3% and a positive currency impact of 3.6%. In the fiscal third quarter of 2025, the net impact of acquisitions and divestitures on the worldwide Innovative Medicine segment operational sales growth was a positive 1.6%, related to CAPLYTA. In the fiscal third quarter of 2025, the negative impact of the STELARA sales decline, due to biosimilar competition, was an approximate 10.7%, 12.0% and 8.6% on worldwide, U.S. and international Innovative Medicine segment operational sales, respectively.

**Major Innovative Medicine therapeutic area sales — Fiscal Third Quarter Ended**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **(Dollars in Millions)** | **September 28, 2025** | **September 29, 2024** | **Total<br>Change** | **Operations<br>Change** | **Currency<br>Change** |
| **Oncology** | **$6529** | **$5380** | **21.3%** | **19.2%** | **2.1%** |
| &nbsp;&nbsp;&nbsp;&nbsp;CARVYKTI | 524 | 286 | 83.5 | 81.4 | 2.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;DARZALEX | 3672 | 3016 | 21.7 | 19.9 | 1.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;ERLEADA | 936 | 790 | 18.4 | 15.3 | 3.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;IMBRUVICA | 695 | 753 | (7.8) | (10.6) | 2.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;RYBREVANT/ LAZCLUZE<sup>(1)</sup> | 198 | 89 | \* | \* | \* |
| &nbsp;&nbsp;&nbsp;&nbsp;TALVEY | 122 | 75 | 60.8 | 59.1 | 1.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;TECVAYLI | 177 | 135 | 31.3 | 29.9 | 1.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;ZYTIGA/ abiraterone acetate | 113 | 150 | (25.1) | (26.8) | 1.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other Oncology | 94 | 86 | 9.7 | 7.7 | 2.0 |
| **Immunology** | **4168** | **4621** | **(9.8)** | **(10.6)** | **0.8** |
| &nbsp;&nbsp;&nbsp;&nbsp;REMICADE | 476 | 419 | 13.6 | 13.3 | 0.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;SIMPONI/ SIMPONI ARIA | 687 | 516 | 32.9 | 31.5 | 1.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;STELARA | 1570 | 2676 | (41.3) | (42.0) | 0.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;TREMFYA | 1424 | 1007 | 41.3 | 40.1 | 1.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other Immunology | 12 | 1 | \* | \* |  |
| **Neuroscience** | **2024** | **1755** | **15.3** | **14.6** | **0.7** |
| &nbsp;&nbsp;&nbsp;&nbsp;CAPLYTA<sup>(2)</sup> | 240 |  | \* | \* |  |
| &nbsp;&nbsp;&nbsp;&nbsp;CONCERTA/ methylphenidate | 140 | 142 | (1.4) | (1.8) | 0.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA | 929 | 1049 | (11.3) | (11.9) | 0.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;SPRAVATO | 459 | 284 | 61.5 | 60.8 | 0.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other Neuroscience | 256 | 281 | (8.9) | (10.2) | 1.3 |
| **Pulmonary Hypertension** | **1115** | **1102** | **1.1** | **0.4** | **0.7** |
| &nbsp;&nbsp;&nbsp;&nbsp;OPSUMIT/ OPSYNVI | 578 | 583 | (0.8) | (1.7) | 0.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;UPTRAVI | 484 | 458 | 5.6 | 5.0 | 0.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other Pulmonary Hypertension | 53 | 60 | (13.1) | (14.1) | 1.0 |
| **Infectious Diseases** | **829** | **836** | **(0.9)** | **(4.3)** | **3.4** |
| &nbsp;&nbsp;&nbsp;&nbsp;EDURANT/rilpivirine | 385 | 330 | 16.4 | 9.5 | 6.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;PREZISTA/ PREZCOBIX/ REZOLSTA/ SYMTUZA | 397 | 449 | (11.6) | (12.6) | 1.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other Infectious Diseases | 47 | 56 | (17.5) | (18.5) | 1.0 |
| **Cardiovascular / Metabolism / Other** | **899** | **884** | **1.7** | **1.2** | **0.5** |
| &nbsp;&nbsp;&nbsp;&nbsp;XARELTO | 635 | 592 | 7.4 | 7.4 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | 264 | 292 | (9.8) | (11.3) | 1.5 |
| **Total Innovative Medicine Sales** | **$15563** | **$14580** | **6.8%** | **5.3%** | **1.5%** |

---

---

| | |
|:---|:---|
| **44** | ![Jhonson&Jhonson.jpg](jnj-20250928_g1.jpg) |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

\*percentage greater than 100% or not meaningful

<sup>(1)</sup> Includes the sales of RYBREVANT and RYBREVANT + LAZCLUZE

<sup>(2)</sup> Acquired with Intra-Cellular Therapies on April 2, 2025

Oncology products achieved operational sales growth of 19.2% as compared to the same period a year ago. Strong sales of DARZALEX (daratumumab) were driven by continued share gains and market growth. Growth of ERLEADA (apalutamide) was due to market growth and continued share gains partially offset by the impact of Medicare Part D redesign. Increased sales of CARVYKTI (ciltacabtagene autoleucel) were driven by continued share gains and site expansion. Additionally, sales from the ongoing launches and share gains of TECVAYLI (teclistamab-cqyv), TALVEY (talquetamab-tgvs) and RYBREVANT (amivantamab)/LAZCLUZE (lazertinib) contributed to the growth. Growth was partially offset by ZYTIGA (abiraterone acetate) due to loss of exclusivity and IMBRUVICA (ibrutinib) declines due to competitive pressures and the impact of Medicare Part D redesign.

Immunology products experienced an operational decline of 10.6% as compared to the same period a year ago primarily due to the decline of STELARA (ustekinumab) sales driven by the impact of biosimilar competition and Medicare Part D redesign. The growth of TREMFYA (guselkumab) was due to share gains and market growth partially offset by unfavorable patient mix and the impact of Medicare Part D redesign. The increase in SIMPONI/SIMPONI ARIA sales was primarily driven by the Merck, Sharp & Dohme return of rights in Europe in the fiscal fourth quarter of 2024. The increase in REMICADE (infliximab) sales was due to a one-time favorable patient mix adjustment and the Merck, Sharp & Dohme return of rights in Europe in the fiscal fourth quarter of 2024.

Sales of STELARA in the United States were approximately $6.7 billion in fiscal 2024. Third parties have filed abbreviated Biologics License Applications with the FDA seeking approval to market biosimilar versions of STELARA. The Company has settled certain litigation under the Biosimilar Price Competition and Innovation Act of 2009. According to patent settlement and license agreements, the Company expects continued launches of biosimilar versions of STELARA in Europe and the United States which will impact the Company's sales of STELARA.

Neuroscience products, which include sales of CAPLYTA (lumateperone) acquired with the Intra-Cellular Therapies (Intra-Cellular) acquisition on April 2, 2025, achieved operational growth of 14.6% as compared to the same period a year ago. Growth of SPRAVATO (esketamine) was driven by continued increased physician and patient demand. Growth was partially offset by the sales decline of INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA primarily due to the impact of Medicare Part D redesign.

Pulmonary Hypertension products achieved operational sales growth of 0.4% as compared to the same period a year ago. The sales growth of UPTRAVI (selexipag) was driven by market growth and inventory dynamics partially offset by the impact of Medicare Part D redesign. The sales decline of OPSUMIT (macitentan)/ OPSYNVI (macitentan/tadalafil) was driven by the impact of Part D redesign and unfavorable patient mix, partially offset by share gains and market growth.

Infectious disease products experienced an operational sales decline of 4.3% as compared to the same period a year ago primarily driven by declines across the portfolio partially offset by growth of EDURANT/rilpivirine.

Cardiovascular / Metabolism / Other products achieved operational growth of 1.2% as compared to the same period a year ago. The growth of XARELTO (rivaroxaban) sales was primarily driven by the impact of Medicare Part D redesign partially offset by continued share loss.

The Inflation Reduction Act (IRA) contains provisions that redesign the Medicare Part D benefit in various ways, including by shifting a greater portion of costs to manufacturers within certain coverage phases and replacing the Part D coverage gap discount program with a new manufacturer discounting program.

The Company maintains a policy that no end customer will be permitted direct delivery of product to a location other than the billing location. This policy impacts contract pharmacy transactions involving non-grantee 340B covered entities for most of the Company's drugs, subject to multiple exceptions. Both grantee and non-grantee covered entities can maintain certain contract pharmacy arrangements under policy exceptions. The Company has been and will continue to offer 340B discounts to covered entities on all of its covered outpatient drugs, and it believes its policy will improve its ability to identify inappropriate duplicate discounts and diversion prohibited by the 340B statute. The 340B Drug Pricing Program is a U.S. federal government program requiring drug manufacturers to provide significant discounts on covered outpatient drugs to covered entities.

---

| | |
|:---|:---|
| Form 10-Q | **45** |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

**MedTech**

The MedTech segment sales in the fiscal nine months of 2025 were $25.0 billion, an increase of 5.6% as compared to the same period a year ago, with an operational increase of 5.3% and a positive currency impact of 0.3%. U.S. MedTech sales increased by 6.6%. International MedTech sales increased by 4.5%, including an operational increase of 3.9% and a positive currency impact of 0.6%. In the fiscal nine months of 2025, the net impact of acquisitions and divestitures on the MedTech segment operational sales growth was a positive 1.6%, primarily related to the Shockwave acquisition.

**Major MedTech franchise sales — Fiscal Nine Months Ended**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **(Dollars in Millions)** | **September 28, 2025** | **September 29, 2024** | **Total<br>Change** | **Operations<br>Change** | **Currency<br>Change** |
| **Surgery** | **$7493** | **$7338** | **2.1%** | **2.1%** | **0.0%** |
| &nbsp;&nbsp;&nbsp;&nbsp;Advanced | 3402 | 3337 | 1.9 | 1.8 | 0.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;General | 4092 | 4001 | 2.3 | 2.3 | 0.0 |
| **Orthopaedics** | **6820** | **6843** | **(0.3)** | **(0.8)** | **0.5** |
| &nbsp;&nbsp;&nbsp;&nbsp;Hips | 1235 | 1220 | 1.3 | 0.9 | 0.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Knees | 1155 | 1147 | 0.7 | 0.3 | 0.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Trauma | 2333 | 2285 | 2.1 | 1.6 | 0.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Spine, Sports & Other | 2096 | 2191 | (4.3) | (5.0) | 0.7 |
| **Cardiovascular** | **6629** | **5645** | **17.4** | **17.1** | **0.3** |
| &nbsp;&nbsp;&nbsp;&nbsp;Electrophysiology | 4209 | 3946 | 6.7 | 6.4 | 0.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Abiomed | 1291 | 1112 | 16.1 | 15.5 | 0.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Shockwave <sup>(1)</sup> | 828 | 306 | \* | \* | \* |
| &nbsp;&nbsp;&nbsp;&nbsp;Other Cardiovascular | 302 | 281 | 7.5 | 7.2 | 0.3 |
| **Vision** | **4048** | **3843** | **5.3** | **4.8** | **0.5** |
| &nbsp;&nbsp;&nbsp;&nbsp;Contact Lenses/Other | 2902 | 2796 | 3.8 | 3.1 | 0.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Surgical | 1147 | 1048 | 9.4 | 9.6 | (0.2) |
| **Total MedTech Sales** | **$24991** | **$23669** | **5.6%** | **5.3%** | **0.3%** |

---

\*Percentage greater than 100% or not meaningful

<sup>(1)</sup> Acquired on May 31, 2024

---

| | |
|:---|:---|
| **46** | ![Jhonson&Jhonson.jpg](jnj-20250928_g1.jpg) |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

MedTech segment sales in the fiscal third quarter of 2025 were $8.4 billion, an increase of 6.8% as compared to the same period a year ago, which included operational growth of 5.6% and a positive currency impact of 1.2%. U.S. MedTech sales increased by 6.6%. International MedTech sales increased by 7.0%, including operational growth of 4.5% and a positive currency impact of 2.5%. In the fiscal third quarter of 2025, the net impact of acquisitions and divestitures on the MedTech segment operational sales growth was a negative 0.1%.

**Major MedTech franchise sales — Fiscal Third Quarter Ended**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **(Dollars in Millions)** | **September 28, 2025** | **September 29, 2024** | **Total<br>Change** | **Operations<br>Change** | **Currency<br>Change** |
| **Surgery** | **$2542** | **$2434** | **4.4%** | **3.3%** | **1.1%** |
| &nbsp;&nbsp;&nbsp;&nbsp;Advanced | 1165 | 1109 | 5.0 | 3.8 | 1.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;General | 1378 | 1325 | 3.9 | 2.9 | 1.0 |
| **Orthopaedics** | **2274** | **2191** | **3.8** | **2.4** | **1.4** |
| &nbsp;&nbsp;&nbsp;&nbsp;Hips | 405 | 381 | 6.4 | 5.1 | 1.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Knees | 377 | 352 | 7.0 | 5.6 | 1.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Trauma | 793 | 761 | 4.2 | 2.9 | 1.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Spine, Sports & Other | 698 | 696 | 0.3 | (1.3) | 1.6 |
| **Cardiovascular** | **2213** | **1966** | **12.6** | **11.6** | **1.0** |
| &nbsp;&nbsp;&nbsp;&nbsp;Electrophysiology | 1418 | 1279 | 10.8 | 9.7 | 1.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Abiomed | 423 | 362 | 16.8 | 15.6 | 1.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Shockwave | 278 | 229 | 21.2 | 20.9 | 0.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other Cardiovascular | 95 | 96 | (0.7) | (1.7) | 1.0 |
| **Vision** | **1400** | **1300** | **7.7** | **6.1** | **1.6** |
| &nbsp;&nbsp;&nbsp;&nbsp;Contact Lenses/Other | 1018 | 968 | 5.2 | 3.5 | 1.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Surgical | 383 | 333 | 14.9 | 13.8 | 1.1 |
| **Total MedTech Sales** | **$8430** | **$7891** | **6.8%** | **5.6%** | **1.2%** |

---

The Surgery franchise achieved operational sales growth of 3.3% as compared to the prior year fiscal third quarter. The operational growth in Advanced Surgery was primarily due to the strength of the portfolio and commercial execution in Biosurgery and Endocutters. The growth was partially offset by competitive pressures in Energy and Endocutters and by the negative impact of China volume-based procurement. The operational growth in General Surgery was primarily driven by technology penetration and upgrades within the differentiated Wound Closure portfolio coupled with commercial execution, partially offset by softness in aesthetics outside the U.S.

The Orthopaedics franchise achieved operational sales growth of 2.4% as compared to the prior year fiscal third quarter. The operational growth in Hips was due to new product launches. The operational growth in Knees was driven by the strength of the ATTUNE portfolio and pull through related to the VELYS Robotic assisted solutions partially offset by trade inventory dynamics and the negative impact of China volume-based procurement. The operational growth in Trauma was primarily driven by recently launched products partially offset by trade inventory dynamics and the negative impact of China volume-based procurement. The operational sales decline in Spine, Sports & Other reflects competitive pressures and price pressures in the U.S. Early Interventional segment partially offset by U.S. spine new product innovations (TriAltis). All platforms were negatively impacted by revenue disruption from the previously announced Orthopaedics restructuring.

Subsequent to the quarter, on October 14, 2025, the Company announced its intention to separate its Orthopaedics business. The Company intends to explore multiple paths to effect the planned separation with a targeted completion within 18 to 24 months after the initial announcement.

The Cardiovascular franchise achieved operational sales growth of 11.6% as compared to the prior year fiscal third quarter. Abiomed sales growth was driven by the continued strong adoption of Impella 5.5 and Impella CP. Shockwave sales growth was driven by Coronary and Peripheral portfolios. Electrophysiology sales growth was driven by procedure growth, commercial execution, new product performance (VARIPULSE, TRUPULSE), strength in competitive mapping, and one-time impacts of installation and inventory, partially offset by competitive pressures in Pulsed Field Ablation catheters.

---

| | |
|:---|:---|
| Form 10-Q | **47** |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

The Vision franchise achieved operational sales growth of 6.1% as compared to the prior year fiscal third quarter. The Contact Lenses/Other operational growth was driven by market growth, continued strong performance in the ACUVUE OASYS 1-Day family of products and continued strategic price actions. The Surgical operational growth was primarily driven by the continued strength of recent product innovations, robust demand and commercial execution.

**Analysis of consolidated earnings before provision for taxes on income**

Consolidated earnings before provision for taxes on income for the fiscal nine months of 2025 was $27.6 billion representing 39.7% of sales as compared to $12.8 billion in the fiscal nine months of 2024, representing 19.3% of sales. The fiscal nine months of 2025 includes the reversal of approximately $7.0 billion, a significant portion of the previously accrued talc reserve. The fiscal nine months of 2024 includes charges for talc matters of approximately $5.1 billion.

Consolidated earnings before provision for taxes on income for the fiscal third quarter of 2025 was $7.5 billion representing 31.2% of sales as compared to $3.3 billion in the fiscal third quarter of 2024, representing 14.9% of sales. The fiscal third quarter of 2024 includes charges for talc matters of approximately $2.0 billion.

**Cost of products sold**

![16070](jnj-20250928_g6.jpg)![16071](jnj-20250928_g7.jpg)

(Dollars in billions. Percentages in chart are as a percent to total sales)

**Fiscal nine months Q3 2025 versus Fiscal nine months Q3 2024**

Cost of products sold increased as a percent to sales driven by:

**•** Unfavorable product mix driven by the decline of STELARA sales in the Innovative Medicine business

**•** Macroeconomic factors in the MedTech business

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;partially offset by

**•** Non-recurring, acquisition related fair value Inventory step-up of $0.2 billion associated with the Shockwave acquisition in the MedTech business in 2024.

The intangible asset amortization expense included in cost of products sold for the fiscal nine months of 2025 and 2024 was $3.4 billion in both periods.

**Q3 2025 versus Q3 2024**

Cost of products sold decreased as a percent to sales primarily driven by:

**•** Lower intangible asset amortization expense and favorable currency in the Innovative Medicine business

**•** Non-recurring, acquisition related fair value Inventory step-up of $0.2 billion associated with the Shockwave acquisition in the MedTech business in 2024.

partially offset by

**•** Unfavorable product mix driven by the decline of STELARA sales in the Innovative Medicine business

**•** Macroeconomic factors in the MedTech business

---

| | |
|:---|:---|
| **48** | ![Jhonson&Jhonson.jpg](jnj-20250928_g1.jpg) |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

The intangible asset amortization expense included in cost of products sold for the fiscal third quarters of 2025 and 2024 was $1.0 billion and $1.2 billion, respectively.

**Selling, marketing and administrative expenses**![17220](jnj-20250928_g8.jpg)![17221](jnj-20250928_g9.jpg)

(Dollars in billions. Percentages in chart are as a percent to total sales)

**Fiscal nine months Q3 2025 versus Fiscal nine months Q3 2024**

Selling, Marketing and Administrative Expenses decreased as a percent to sales driven by:

**•** Corporate administrative expense rationalization

**•** Planned leverage and phasing of investments in the Innovative Medicine business

partially offset by

**•** Increased investment related to the acquisitions of Intra-Cellular (CAPLYTA) and Shockwave

**Q3 2025 versus Q3 2024**

Selling, Marketing and Administrative Expenses increased as a percent to sales primarily driven by:

**•** Increased investment related to the recent acquisition of Intra-Cellular (CAPLYTA) and commercial investment in recent product launches in the Innovative Medicine business

partially offset by

**•** Expense leveraging in the Medtech business

**Research and development expense**

Research and development expense by segment of business was as follows:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Fiscal Third Quarter Ended** | **Fiscal Third Quarter Ended** | **Fiscal Third Quarter Ended** | **Fiscal Third Quarter Ended** | **Fiscal Nine Months Ended** | **Fiscal Nine Months Ended** | **Fiscal Nine Months Ended** | **Fiscal Nine Months Ended** |
| | **2025** | **2025** | **2024** | **2024** | **2025** | **2025** | **2024** | **2024** |
|<br>**(Dollars in Millions)** | **Amount** | **% of Sales\*** | **Amount** | **% of Sales\*** | **Amount** | **% of Sales\*** | **Amount** | **% of Sales\*** |
| Innovative Medicine | $2944 | 18.9% | $4213 | 28.9% | $8361 | 18.7% | $9831 | 23.1% |
| MedTech | 728 | 8.6 | 739 | 9.4 | 2052 | 8.2 | 2103 | 8.9 |
| **Total research and development expense** | **$3672** | **15.3%** | **$4952** | **22.0%** | **$10413** | **15.0%** | **$11934** | **18.0%** |
| Percent increase/(decrease) over the prior year | (25.8%) |  |  |  | (12.7%) |  |  |  |
| \*As a percent to segment sales |  |  |  |  |  |  |  |  |

---

---

| | |
|:---|:---|
| Form 10-Q | **49** |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

**Fiscal nine months Q3 2025 versus Fiscal nine months Q3 2024**

Research and Development decreased as a percent to sales primarily driven by:

**•** Expense of $1.25 billion to secure the global rights to the NM26 bispecific antibody (Yellow Jersey acquisition) in 2024

**•** Planned leverage and phasing of investments in the Innovative Medicine business

**Q3 2025 versus Q3 2024**

Research and Development decreased as a percent to sales primarily driven by:

**•** Expense of $1.25 billion to secure the global rights to the NM26 bispecific antibody (Yellow Jersey acquisition) in 2024

**•** Phasing of investments in the Innovative Medicine business

**In-process research and development (IPR&D) impairments**

In the fiscal nine months of 2024, the Company recorded a charge of approximately $0.2 billion associated with the M710 (biosimilar) asset acquired with Momenta in 2020. There was also a partial impairment of this asset for $0.2 billion in the fiscal third quarter of 2023. This asset is now fully impaired.

**Interest (income) expense**

Interest (income) expense in the fiscal nine months of 2025 was net income of $62 million as compared to net income of $433 million in the fiscal nine months of 2024. Interest income in the fiscal nine months of 2025 decreased as compared to the prior year driven by lower interest rates earned on cash balances. Interest expense was higher due to a higher average debt balance at higher interest rates. Interest (income) expense in the fiscal third quarter of 2025 was net expense of $18 million as compared to net income of $99 million in the fiscal third quarter of 2024. Interest income in the fiscal third quarter of 2025 decreased as compared to the prior year driven by a lower average cash balance. Interest expense was higher due to a higher average debt balance. The balance of cash, cash equivalents and current marketable securities was $18.6 billion at the end of the fiscal third quarter of 2025 as compared to $20.3 billion at the end of the fiscal third quarter of 2024. The Company's debt position was $45.8 billion as of September 28, 2025, as compared to $35.8 billion the same period a year ago.

**Other (income) expense, net\***

**Fiscal nine months Q3 2025 versus Fiscal nine months Q3 2024**

Other (income) expense, net for the fiscal nine months of 2025 reflected an increase in income of $12.6 billion as compared to the prior year primarily due to the following:

---

| | | | |
|:---|:---|:---|:---|
| **Fiscal Nine Months**<br>**(Dollars in Billions)(Income)/Expense** |<br>**September 28, 2025** |<br>**September 29, 2024** |<br>**Change** |
| Litigation related<sup>(1)</sup> | $(6.9) | 5.5 | (12.4) |
| Employee benefit plan related | (0.4) | (0.7) | 0.3 |
| Changes in the fair value/sale of securities<sup>(2)</sup> | (0.3) | 0.4 | (0.7) |
| Monetization of royalty rights | 0.0 | (0.3) | 0.3 |
| Acquisition, Integration and Divestiture related | 0.4 | 0.7 | (0.3) |
| Other | (0.5) | (0.7) | 0.2 |
| Total Other (Income) Expense, Net | $(7.7) | 4.9 | (12.6) |

---

<sup>(1)</sup> The fiscal nine months of 2025 includes the reversal of approximately $7.0 billion, a significant portion of the previously accrued talc reserve. The fiscal nine months of 2024 includes charges of approximately $5.1 billion for talc matters. For additional details related to talc refer to Note 11 to the Consolidated Financial Statements.

<sup>(2)</sup> The fiscal nine months of 2024 includes the loss on the completion of the debt for equity exchange of the retained stake in Kenvue

---

| | |
|:---|:---|
| **50** | ![Jhonson&Jhonson.jpg](jnj-20250928_g1.jpg) |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

**Q3 2025 versus Q3 2024**

Other (income) expense, net for the fiscal third quarter of 2025 reflected an increase in income of $2.3 billion as compared to the prior year primarily due to the following:

---

| | | | |
|:---|:---|:---|:---|
| **Fiscal Third Quarter**<br>**(Dollars in Billions)(Income)/Expense** |<br>**September 28, 2025** |<br>**September 29, 2024** |<br>**Change** |
| Acquisition, Integration and Divestiture related | $0.1 | 0.1 | 0.0 |
| Litigation related<sup>(1)</sup> | 0.0 | 2.4 | (2.4) |
| Monetization of royalty rights | 0.0 | (0.3) | 0.3 |
| Employee benefit plan related | (0.1) | (0.2) | 0.1 |
| Changes in the fair value/sale of securities | (0.4) | 0.0 | (0.4) |
| Other | (0.1) | (0.2) | 0.1 |
| Total Other (Income) Expense, Net | $(0.5) | 1.8 | (2.3) |

---

<sup>(1)</sup> The fiscal third quarter of 2024 includes charges for talc matters of approximately $2.0 billion.

\*Other (income) expense, net is the account where the Company records gains and losses related to the sale and write-down of certain investments in equity securities held by Johnson & Johnson Innovation - JJDC, Inc. (JJDC), changes in the fair value of securities, gains and losses on divestitures, gains and losses on sale of assets, certain transactional currency gains and losses, acquisition-related costs, litigation accruals and settlements, investment (income)/loss related to employee benefit plans, as well as royalty income.

**Segment income before tax**

Income before tax by segment of business for the fiscal nine months were as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Income Before Tax** | **Income Before Tax** | **Segment Sales** | **Segment Sales** | **Percent of Segment Sales** | **Percent of Segment Sales** |
|<br>**(Dollars in Millions)** | **September 28, 2025** | **September 29, 2024** | **September 28, 2025** | **September 29, 2024** | **September 28, 2025** | **September 29, 2024** |
| Innovative Medicine | $17208 | $14910 | $44638 | $42632 | 38.6% | 35.0% |
| MedTech | 3912 | 3668 | 24991 | 23669 | 15.7 | 15.5 |
| Segment total | 21120 | 18578 | 69629 | 66301 | 30.3 | 28.0 |
| (Income) Expenses not allocated to segments<sup>(1)</sup> | (6495) | 5778 |  |  |  |  |
| Earnings before provision for taxes on income | $27615 | $12800 | $69629 | $66301 | 39.7% | 19.3% |

---

<sup>(1)</sup> Amounts not allocated to segments include interest (income) expense, certain litigation expenses and general corporate (income) expense. The fiscal nine months of 2025 includes the reversal of approximately $7.0 billion, a significant portion of the previously accrued talc reserve. The fiscal nine months of 2024 includes charges for talc matters of $5.1 billion. The fiscal nine months of 2024 includes a loss of approximately $0.4 billion related to the debt to equity exchange of the Company's remaining shares of Kenvue Common Stock.

**Innovative Medicine segment**

The Innovative Medicine segment income before tax as a percent of sales in the fiscal nine months of 2025 was 38.6% versus 35.0% for the same period a year ago. The increase in the income before tax as a percent of sales for the fiscal nine months of 2025 as compared to the prior year was primarily driven by the following:

**•** Expense of $1.25 billion to secure the global rights to the NM26 bispecific antibody (Yellow Jersey acquisition) in 2024

**•** Litigation expense of $0.4 billion in 2024 primarily related to Risperdal Gynecomastia.

• Higher favorable change in the fair value of securities of $0.1 billion in 2025

**•** Lower amortization expense of $0.1 billion in 2025

**•** An In-process research and development impairment of $0.2 billion in 2024 related to the M710 (biosimilar) asset acquired with Momenta in 2020

**•** Restructuring charge of $0.1 billion in 2024

---

| | |
|:---|:---|
| Form 10-Q | **51** |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

partially offset by

**•** Monetization of royalty rights of $0.3 billion in 2024

**•** Unfavorable Product mix and the impact of Medicare Part D redesign

**•** Increased investment related to the acquisition of Intra-Cellular (CAPLYTA)

**MedTech segment**

The MedTech segment income before tax as a percent of sales in the fiscal nine months of 2025 was 15.7% versus 15.5% for the same period a year ago. The increase in the income before tax as a percent of sales for the fiscal nine months of 2025 was primarily driven by the following:

• Lower acquisition and integration related costs of $0.2 billion in 2025 versus $0.9 billion in 2024 primarily related to the Shockwave acquisition

• Gain on the sale of securities of $0.2 billion in 2025

partially offset by

**•** Higher restructuring related costs of $0.3 billion in 2025 versus $0.1 billion in 2024

• A gain of $0.2 billion related to the Acclarent divestiture in 2024

**•** Macroeconomic factors in Cost of products sold

Income before tax by segment of business for the fiscal third quarters were as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Income Before Tax** | **Income Before Tax** | **Segment Sales** | **Segment Sales** | **Percent of Segment Sales** | **Percent of Segment Sales** |
|<br>**(Dollars in Millions)** | **September 28, 2025** | **September 29, 2024** | **September 28, 2025** | **September 29, 2024** | **September 28, 2025** | **September 29, 2024** |
| Innovative Medicine | $6446 | $4482 | $15563 | $14580 | 41.4% | 30.7% |
| MedTech | 1287 | 1059 | 8430 | 7891 | 15.3 | 13.4 |
| Segment total | 7733 | 5541 | 23993 | 22471 | 32.2 | 24.7 |
| (Income) Expenses not allocated to segments<sup>(1)</sup> | 240 | 2203 |  |  |  |  |
| Earnings before provision for taxes on income | $7493 | $3338 | $23993 | $22471 | 31.2% | 14.9% |

---

<sup>(1)</sup> Amounts not allocated to segments include interest (income) expense, certain litigation expenses and general corporate (income) expense. The fiscal third quarter of 2024 includes charges for talc matters of $2.0 billion. For additional details related to talc refer to Note 11 to the Consolidated Financial Statements.

**Innovative Medicine segment**

The Innovative Medicine segment income before tax as a percent of sales in the fiscal third quarter of 2025 was 41.4% versus 30.7% for the same period a year ago. The increase in the income before tax as a percent of sales for the fiscal third quarter of 2025 as compared to the prior year was primarily driven by the following:

**•** Expense of $1.25 billion to secure the global rights to the NM26 bispecific antibody (Yellow Jersey acquisition) in 2024

**•** Litigation expense of $0.4 billion in 2024 primarily related to Risperdal Gynecomastia

• Higher favorable change in the fair value of securities of $0.1 billion in 2025

partially offset by

**•** Monetization of royalty rights of $0.3 billion in 2024

**•** Unfavorable Product mix and the impact of Medicare Part D redesign

**•** Increased investment related to the acquisition of Intra-Cellular (CAPLYTA)

---

| | |
|:---|:---|
| **52** | ![Jhonson&Jhonson.jpg](jnj-20250928_g1.jpg) |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

**MedTech segment**

The MedTech segment income before tax as a percent of sales in the fiscal third quarter of 2025 was 15.3% versus 13.4% for the same period a year ago. The increase in the income before tax as a percent of sales for the fiscal third quarter of 2025 as compared to the prior year was primarily driven by the following:

• Higher acquisition and integration related costs of $0.2 billion in 2024 primarily related to the Shockwave acquisition

• Gain on the sale of securities of $0.2 billion in 2025

**•** Leveraging in Selling, Marketing and Administrative expenses

partially offset by

**•** Macroeconomic factors in Cost of products sold

**•** Higher restructuring related costs of $0.1 billion in 2025

**Restructuring**

In fiscal 2025, the company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting certain non-strategic product lines and optimize select sites across the network. The pre-tax restructuring expense was $128 million in the fiscal third quarter of 2025, of which $35 million was recorded in Restructuring and $93 million in Other income and expense on the Consolidated Statement of Earnings. The pre-tax restructuring expense was $157 million in the fiscal nine months of 2025, of which $64 million was recorded in Restructuring and $93 million in Other income and expense on the Consolidated Statement of Earnings. The pre-tax restructuring expense in the fiscal third quarter and fiscal nine months of 2025 primarily included costs related to asset impairments as well as market and product exits. The estimated costs of the total program are between $0.9 billion - $1.0 billion and is expected to be substantially completed by the end of fiscal year 2026.

In fiscal 2023, the Company initiated a restructuring program of its Orthopaedics franchise within its MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The pre-tax restructuring expense was $40 million in the fiscal third quarter of 2025, of which $28 million was recorded in Restructuring and $12 million in Cost of products sold on the Consolidated Statement of Earnings primarily for costs related to market and product exits. The pre-tax restructuring expense was $145 million in the fiscal nine months of 2025, of which $80 million was recorded in Restructuring, $35 million in Cost of products sold and $30 million in Other (Income)/Expense on the Consolidated Statement of Earnings primarily for costs related to asset impairments as well as market and product exits. The pre-tax restructuring expense was immaterial in the fiscal third quarter of 2024 and $107 million in the fiscal nine months of 2024, and primarily included costs related to market and product exits. Total project costs of approximately $0.6 billion have been recorded since the restructuring was announced. The estimated costs of the total program are between $0.7 billion - $0.8 billion and will be substantially completed by the end of fiscal year 2025.

In fiscal 2023, the Company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. The pre-tax restructuring charge of $100 million in the fiscal nine months of 2024 included the termination of partnered and non-partnered program costs and asset impairments. The program was completed in the fiscal fourth quarter of 2024.

For further details related to the restructuring refer to Note 12 to the Consolidated Financial Statements.

**Provision for taxes on income**

The worldwide effective income tax rate for the fiscal nine months was 21.5% in 2025 and 16.9% in 2024.

On December 15, 2022, the European Union (EU) Member States formally adopted the EU's Pillar Two Directive, which generally provides for a minimum effective tax rate of 15%, as established by the Organization for Economic Co-operation and Development (OECD) Pillar Two Framework that was supported by over 130 countries worldwide. Several EU and non-EU countries have enacted Pillar Two legislation with an initial effective date of January 1, 2024, with other aspects of the law effective in 2025 or later. While countries continue to enact new provisions or issue new regulations this could have an impact to the Company's effective tax rate. The Company will continue to monitor further developments to determine any potential impact in the countries in which we operate, such as the recently announced understanding between the U.S. and the G7 of a side-by-side system that would fully exclude U.S. parented groups from certain provisions of the Pillar Two Framework.

For further details related to the fiscal 2025 provision for taxes refer to Note 5 to the Consolidated Financial Statements.

---

| | |
|:---|:---|
| Form 10-Q | **53** |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

**Liquidity and capital resources**

**Acquisitions (net of cash acquired)**

![28852](jnj-20250928_g10.jpg)

**Proceeds from the disposal of assets/businesses, net**

![28907](jnj-20250928_g11.jpg)

 **Dividends to shareholders**

![28936](jnj-20250928_g12.jpg)

**Cash flows**

Cash and cash equivalents were $18.2 billion at the end of the fiscal third quarter of 2025 as compared with $24.1 billion at the end of fiscal year 2024. The primary sources and uses of cash that contributed to the $5.9 billion decrease were:

---

| | |
|:---|:---|
| (Dollars In Billions) | (Dollars In Billions) |
| 24.1 | Q4 2024 Cash and cash equivalents balance |
| 17.2 | net cash generated from operating activities |
| (19.1) | net cash used for investing activities |
| (4.2) | net cash used for financing activities |
| 0.2 | effect of exchange rate changes on cash and cash equivalents |
| $18.2 | Q3 2025 Cash and cash equivalents |

---

In addition, the Company had $0.3 billion in marketable securities at the end of the fiscal third quarter of 2025 and $0.4 billion at the end of fiscal year 2024.

Cash flow from operations of $17.2 billion was the result of:

---

| | |
|:---|:---|
| (Dollars In Billions) | (Dollars In Billions) |
| $21.7 | Net earnings |
| 11.8 | non-cash expenses and other adjustments primarily for depreciation and amortization, stock-based compensation, deferred tax provision, charge for acquired in-process research and development assets and asset write-downs partially offset by the net gain on sale of assets/businesses |
| (3.6) | an increase in accounts receivable and inventories |
| 1.1 | an increase in accounts payable and accrued liabilities |
| (7.7) | an increase in other current and non-current assets |
| (6.2) | a decrease in other current and non-current liabilities |
| 0.1 | rounding |
| $17.2 | Net cash flows from operations |

---

---

| | |
|:---|:---|
| **54** | ![Jhonson&Jhonson.jpg](jnj-20250928_g1.jpg) |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

Cash flow used for investing activities of $19.1 billion was primarily from:

---

| | |
|:---|:---|
| (Dollars In Billions) | (Dollars In Billions) |
| $(3.0) | additions to property, plant and equipment |
| 0.4 | proceeds from the disposal of assets/businesses, net |
| (14.5) | acquisitions, net of cash acquired |
| (0.4) | acquired in-process research and development assets/related milestones |
| 0.8 | net sales of investments |
| (2.3) | credit support agreements activity, net |
| (0.1) | Other and rounding |
| $(19.1) | Net cash used for investing activities |

---

Cash flow used for financing activities of $4.2 billion was primarily from:

---

| | |
|:---|:---|
| (Dollars In Billions) | (Dollars In Billions) |
| $(9.3) | dividends to shareholders |
| (4.0) | repurchase of common stock |
| 7.5 | net proceeds from short and long term debt |
| 1.8 | proceeds from stock options exercised/employee withholding tax on stock awards, net |
| (0.2) | credit support agreements activity, net |
| $(4.2) | Net cash used for financing activities |

---

The following table summarizes income taxes paid net of tax refunds:

---

| | | |
|:---|:---|:---|
| **(Dollars in Millions)** | **September 28, 2025** | **December 29, 2024** |
| Total U.S. <sup>(1)</sup> | $3740 | 4156 |
| Total Foreign | 2024 | 2558 |
| **Total income taxes paid net of tax refunds** | $**5764** | **6714** |

---

<sup>(1)</sup> Represents Federal and State taxes and includes TCJA foreign undistributed earnings payments of $2.5 billion in 2025 and $2.0 billion in 2024

The Company has access to substantial sources of funds at numerous banks worldwide and has the ability to issue up to $20 billion in Commercial Paper. Furthermore, in June 2025, the Company secured a new 364-day Credit Facility of $10 billion (expiration on June 24, 2026) which may be used for general corporate purposes including to support our commercial paper borrowings. Interest charged on borrowings under the credit line agreement is based on either Secured Overnight Financing Rate (SOFR) Reference Rate or other applicable market rate as allowed plus applicable margins. Commitment fees under the agreement are not material.

As of September 28, 2025, the Company had cash, cash equivalents and marketable securities of approximately $18.6 billion and had approximately $45.8 billion of notes payable and long-term debt for a net debt position of $27.2 billion as compared to the prior year fiscal third quarter net debt position of $15.5 billion. In the fiscal first quarter of 2025, the Company issued senior unsecured notes for approximately $9.2 billion. The net proceeds from this offering were used to fund the Intra-Cellular Therapies, Inc. acquisition for approximately $14.5 billion which closed on April 2, 2025, and for general corporate purposes. For additional details on borrowings, see Note 4 to the Consolidated Financial Statements. The Company anticipates that operating cash flows, the ability to raise funds from external sources, borrowing capacity from existing committed credit facilities and access to the commercial paper markets will continue to provide sufficient resources to fund operating needs, including the Company's remaining balance of approximately $3.8 billion related to talc matters, $2.0 billion related to the current portion of Corporate bonds due and the remaining approximately $1.1 billion to settle opioid litigation (See Note 11 to the Consolidated Financial Statements for additional details). In addition, the Company monitors the global capital markets on an ongoing basis and from time to time may raise capital when market conditions are favorable.

---

| | |
|:---|:---|
| Form 10-Q | **55** |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

**Dividends**

On July 16, 2025, the Board of Directors declared a regular cash dividend of $1.30 per share, payable on September 9, 2025, to shareholders of record as of August 26, 2025.

On October 14, 2025, the Board of Directors declared a regular cash dividend of $1.30 per share, payable on December 9, 2025, to shareholders of record as of November 25, 2025. The Company expects to continue the practice of paying regular quarterly cash dividends.

**Other information**

**New accounting pronouncements**

Refer to Note 1 to the Consolidated Financial Statements for new accounting pronouncements.

**Economic and market factors**

In July 2023, Janssen Pharmaceuticals, Inc. (Janssen) filed litigation against the U.S. Department of Health and Human Services as well as the Centers for Medicare and Medicaid Services challenging the constitutionality of the IRA's Medicare Drug Price Negotiation Program. The litigation requests a declaration that the IRA violates Janssen's rights under the First Amendment and the Fifth Amendment to the Constitution and therefore that Janssen is not subject to the IRA's mandatory pricing scheme. The impact of the IRA on our business and the broader pharmaceutical industry remains uncertain, as litigation filed by Janssen and other pharmaceutical companies remains ongoing and while CMS has publicly announced the maximum fair price for each of the selected drugs, implementation of the program is still in progress. In September 2025, a majority of the Third Circuit panel denied Janssen's appeal of the district court's decision.

The Company operates in certain countries where the economic conditions continue to present significant challenges. The Company continues to monitor these situations and take appropriate actions. Inflation rates and currency exchange rates continue to have an effect on worldwide economies and, consequently, on the way the Company operates. The Company has accounted for operations in Venezuela, Argentina, Turkey and Egypt (beginning in the fiscal fourth quarter of 2024) as highly inflationary, as the prior three-year cumulative inflation rate surpassed 100%. In the face of increasing costs, the Company strives to maintain its profit margins through cost reduction programs, productivity improvements and periodic price increases.

The long-term implications of regional conflicts on the Company are difficult to predict. The financial impact of known existing conflicts in the fiscal third quarter of 2025 was not material.

Governments around the world consider various proposals to make changes to tax laws, which may include increasing or decreasing existing statutory tax rates. In connection with various government initiatives, companies are required to disclose more information to tax authorities on operations around the world, which may lead to greater audit scrutiny of profits earned in other countries. A change in statutory tax rate in any country would result in the revaluation of the Company's deferred tax assets and liabilities related to that particular jurisdiction in the period in which the new tax law is enacted. This change would result in an expense or benefit recorded to the Company's Consolidated Statement of Earnings. The Company closely monitors these proposals as they arise in the countries where it operates. Changes to the statutory tax rate may occur at any time, and any related expense or benefit recorded may be material to the fiscal quarter and year in which the law change is enacted.

The Company may be further impacted by the imposition of tariffs, trade protection measures or other policies adopted by any jurisdiction that favor domestic companies and technologies over foreign competitors.

The Company faces various worldwide health care changes that may continue to result in pricing pressures that include health care cost containment and government legislation relating to sales, promotions and reimbursement of health care products.

Changes in the behavior and spending patterns of purchasers of healthcare products and services, including delaying medical procedures, rationing prescription medications, reducing the frequency of physician visits and foregoing healthcare insurance coverage, may continue to impact the Company's businesses.

The Company faces regular intellectual property challenges from third parties, including generic and biosimilar manufacturers, seeking to manufacture and market generic and biosimilar versions of key pharmaceutical products prior to the expiration of the applicable patents. These challengers file Abbreviated New Drug Applications or abbreviated Biologics License Applications with the FDA or otherwise challenged the coverage and/or validity of the Company's patents. In the event the Company is not successful in defending the patent claims challenged in the resulting lawsuits, generic or biosimilar versions of the products at issue may be introduced to the market, resulting in the potential for substantial market share and revenue losses for those products, and which may result in a non-cash impairment charge in any associated intangible asset. There is also risk that one or more competitors

---

| | |
|:---|:---|
| **56** | ![Jhonson&Jhonson.jpg](jnj-20250928_g1.jpg) |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

could launch a generic or biosimilar version of the product at issue following regulatory approval even though one or more valid patents are in place.

**Item 3 — Quantitative and qualitative disclosures about market risk**

There has been no material change in the Company's assessment of its sensitivity to market risk since its presentation set forth in Item 7A, "Quantitative and Qualitative Disclosures About Market Risk," in its Annual Report on Form 10-K for the fiscal year ended December 29, 2024.

**Item 4 — Controls and procedures**

Disclosure controls and procedures. At the end of the period covered by this report, the Company evaluated the effectiveness of the design and operation of its disclosure controls and procedures. The Company's disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is accumulated and communicated to the Company's management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Joaquin Duato, Chief Executive Officer; Chairman, Executive Committee and Joseph J. Wolk, Executive Vice President, Chief Financial Officer, reviewed and participated in this evaluation. Based on this evaluation, Messrs. Duato and Wolk concluded that, as of the end of the period covered by this report, the Company's disclosure controls and procedures were effective.

Internal control. During the period covered by this report, there were no changes in the Company's internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting. The Company continues to monitor and assess the effectiveness of the design and operation of its disclosure controls and procedures.

The Company is implementing a multi-year, enterprise-wide initiative to integrate, simplify and standardize processes and systems for the human resources, information technology, procurement, supply chain and finance functions. These are enhancements to support the growth of the Company's financial shared service capabilities and standardize financial systems. This initiative is not in response to any identified deficiency or weakness in the Company's internal control over financial reporting. In response to this initiative, the Company has and will continue to align and streamline the design and operation of its financial control environment.

---

| | |
|:---|:---|
| Form 10-Q | **57** |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

Part II — Other information

**Item 1 — Legal proceedings**

The information called for by this item is incorporated herein by reference to Note 11 included in Part I, Item 1, Financial Statements (unaudited) — Notes to Consolidated Financial Statements.

**Item 2 — Unregistered sales of equity securities and use of proceeds**

(c) Purchases of Equity Securities by the Issuer and Affiliated Purchasers.

The following table provides information with respect to Common Stock purchases by the Company during the fiscal third quarter of 2025. Common stock purchases on the open market are made as part of a systematic plan to meet the needs of the Company's compensation programs. The repurchases below also include the stock-for-stock option exercises that settled in the fiscal third quarter.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Fiscal Month Period** | **Total Number**<br>**of Shares**<br>**Purchased**<sup>(1)</sup> | **Avg. Price<br>Per Share** | **Total Number of**<br>**Shares**<br>**Purchased as**<br>**Part of Publicly**<br>**Announced Plans**<br>**or Programs** | **Maximum Number of**<br>**Shares that May Yet**<br>**Be Purchased Under**<br>**the Plans or Programs** |
| June 30, 2025 through July 27, 2025 | 868779 | 167.40 |  |  |
| July 28, 2025 through August 24, 2025 | 4103196 | 175.64 |  |  |
| August 25, 2025 through September 28, 2025 | 5828766 | 177.70 |  |  |
| **Total** | **10800741** | **176.09** | **—** | **—** |

---

<sup>(1)</sup> During the fiscal third quarter of 2025, the Company repurchased an aggregate of 10,800,741 shares of Johnson & Johnson Common Stock in open-market transactions, all of which were purchased as part of a systematic plan to meet the needs of the Company's compensation programs.

---

| | |
|:---|:---|
| **58** | ![Jhonson&Jhonson.jpg](jnj-20250928_g1.jpg) |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

**Item 5 — Other information**

*Securities trading plans of Directors and Executive Officers*. During the fiscal third quarter of 2025, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) informed us of the adoption or termination of a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," each as defined in Item 408 of Regulation S-K.

**Item 6 — Exhibits**

<u>[Exhibit 31.1](a20253qex311ceocertificati.htm)</u>Certification of Chief Executive Officer under Rule 13a-14(a) of the Securities Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 — Filed with this document.

<u>[Exhibit 31.2](a20253qex312cfocertificati.htm)</u>Certification of Chief Financial Officer under Rule 13a-14(a) of the Securities Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 — Filed with this document.

<u>[Exhibit 32.1](a20253qex321ceocertificati.htm)</u>Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 — Furnished with this document.

<u>[Exhibit 32.2](a20253qex322cfocertificati.htm)</u> Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 — Furnished with this document.

Exhibit 101:

---

| | |
|:---|:---|
| EX-101.INS | Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document |
| EX-101.SCH | Inline XBRL Taxonomy Extension Schema |
| EX-101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase |
| EX-101.LAB | Inline XBRL Taxonomy Extension Label Linkbase |
| EX-101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase |
| EX-101.DEF | Inline XBRL Taxonomy Extension Definition Document |
| Exhibit 104: | Cover Page Interactive Data File––the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |

---

---

| | |
|:---|:---|
| Form 10-Q | **59** |

---

------

<u>[**Table of Contents**](#i056ba067237e4aedb74b3ac320710725_7)</u>

**Signatures**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

<u>Date: October 22, 2025</u>

<u>Date: October 22, 2025</u>

---

| |
|:---|
| **JOHNSON & JOHNSON** |
| (Registrant) |

---

---

| | |
|:---|:---|
| By | /s/ **J. J. Wolk** |
| | **J. J. Wolk**, Executive Vice President, Chief Financial Officer (Principal Financial Officer)  |

---

---

| | |
|:---|:---|
| By | /s/ **R. J. Decker Jr.** |
| | **R. J. Decker Jr.**, Controller (Principal Accounting Officer) |

---

---

| | |
|:---|:---|
| **60** | ![Jhonson&Jhonson.jpg](jnj-20250928_g1.jpg) |

---

## Exhibit 31.1

**Exhibit 31.1**

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT

I, Joaquin Duato, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended September 28, 2025 (the "report") of Johnson & Johnson (the "Company");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. The Company's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the Company and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the Company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the Company's internal control over financial reporting that occurred during the Company's most recent fiscal quarter (the Company's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. The Company's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company's auditors and the audit committee of the Company's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial reporting.

---

| |
|:---|
| /s/ Joaquin Duato |
| Joaquin Duato<br>*Chief Executive Officer* |

---

Date: October 22, 2025

## Exhibit 31.2

**Exhibit 31.2**

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT

I, Joseph J. Wolk, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended September 28, 2025 (the "report") of Johnson & Johnson (the "Company");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. The Company's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the Company and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the Company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the Company's internal control over financial reporting that occurred during the Company's most recent fiscal quarter (the Company's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. The Company's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company's auditors and the audit committee of the Company's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial reporting.

---

| |
|:---|
| /s/ Joseph J. Wolk |
| Joseph J. Wolk<br>*Chief Financial Officer* |

---

Date: October 22, 2025

## Exhibit 32.1

**Exhibit 32.1**

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT

The undersigned, Joaquin Duato, the Chief Executive Officer of Johnson & Johnson, a New Jersey corporation (the "Company"), pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, hereby certifies that, to the best of my knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;&nbsp;&nbsp;&nbsp;the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 28, 2025 (the "Report") fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;&nbsp;&nbsp;&nbsp;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| |
|:---|
| /s/ Joaquin Duato |
| Joaquin Duato<br>*Chief Executive Officer* |

---

Dated: October 22, 2025

This certification is being furnished to the SEC with this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability of that section.

## Exhibit 32.2

**Exhibit 32.2**

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT

The undersigned, Joseph J. Wolk, the Chief Financial Officer of Johnson & Johnson, a New Jersey corporation (the "Company"), pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, hereby certifies that, to the best of my knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;&nbsp;&nbsp;&nbsp;the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 28, 2025 (the "Report") fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;&nbsp;&nbsp;&nbsp;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| |
|:---|
| /s/ Joseph J. Wolk |
| Joseph J. Wolk<br>*Chief Financial Officer* |

---

Dated: October 22, 2025

This certification is being furnished to the SEC with this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability of that section.

<br>